

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 February 2006 (23.02.2006)

PCT

(10) International Publication Number
WO 2006/018308 A1

(51) International Patent Classification:

C07D 217/04 (2006.01) **C07D 413/12** (2006.01)
C07D 413/14 (2006.01) **C07D 417/12** (2006.01)
C07D 409/12 (2006.01) **A61K 31/47** (2006.01)
C07D 401/12 (2006.01) **A61K 31/4725** (2006.01)
C07D 513/04 (2006.01) **A61P 25/00** (2006.01)

Luz [ES/ES]; Avda. Mare de Déu de Montserrat, 221, E-08041 Barcelona (ES). **BUSCHMANN, Helmut H.** [DE/ES]; Avda. Mare de Déu de Montserrat, 221, E-08041 Barcelona (ES).

(74) Agent: **BERNARDO NORIEGA, Francisco**; ABG PATENTES, S.L., Orense, 68 7th floor, E-28020 Madrid (ES).

(21) International Application Number:

PCT/EP2005/008978

(22) International Filing Date: 18 August 2005 (18.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10/920,738 18 August 2004 (18.08.2004) US
P 200402049 18 August 2004 (18.08.2004) ES
04380171.1 18 August 2004 (18.08.2004) EP

(71) Applicant (for all designated States except US): **LABORATORIOS DEL DR. ESTEVE, S.A.** [ES/ES]; Avda. Mare de Déu de Montserrat, 221, E-08041 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TORRENS JOVER, Antoni** [ES/ES]; Avda. Mare de Déu de Montserrat, 221, E-08041 Barcelona (ES). **MAS PRIÓ, Josep** [ES/ES]; Avda. Mare de Déu de Montserrat, 221, E-08041 Barcelona (ES). **YENES MÍNGUEZ, Susana** [ES/ES]; Avda. Mare de Déu de Montserrat, 221, E-08041 Barcelona (ES). **GARCÍA LÓPEZ, Mónica** [ES/ES]; Avda. Mare de Déu de Montserrat, 221, E-08041 Barcelona (ES). **DORDAL ZUERAS, Alberto** [ES/ES]; Avda. Mare de Déu de Montserrat, 221, E-08041 Barcelona (ES). **ROMERO ALONSO,**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 5-HT₇ RECEPTOR ANTAGONISTS



(57) Abstract: The invention relates to compounds of formula (I) having pharmacological activity towards the 5-HT₇ receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

WO 2006/018308 A1

5-HT₇ RECEPTOR ANTAGONISTS

FIELD OF THE INVENTION

The present invention relates to compounds having pharmacological activity towards the 5-HT₇ receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment and or prophylaxis of a disease in which 5-HT₇ is involved, such as CNS disorders.

BACKGROUND OF THE INVENTION

The search for new therapeutic agents has been greatly aided in recent years by better understanding of the structure of proteins and other biomolecules associated with target diseases. One important class of proteins that has been the subject of extensive study is the family of 5-hydroxytryptamine (serotonin, 5-HT) receptors. The 5-HT₇ receptor discovered in 1993 belongs to this family and has attracted great interest as a valuable new drug target (Terrón, J.A. *Idrugs*, **1998**, vol. 1, no. 3, pages 302-310: "*The 5HT₇ receptor: A target for novel therapeutic avenues?*").

5-HT₇ receptors have been cloned from rat, mouse, guinea pig and human cDNA and exhibit a high degree of interspecies homology (approx. 95%), but it is unique in that it has a low sequence homology with other 5-HT receptors (less than 40%). Its expression pattern, in particular structures of the central nervous system (CNS) (highest in hypothalamus (in particular suprachiasmatic nuclei) and thalamus) and other peripheral tissues (spleen, kidney, intestinal, heart and coronary artery), implicates the 5-HT₇ receptor in a variety of functions and pathologies. This idea is reinforced by the fact that several therapeutic agents, such as tricyclic antidepressants, typical and atypical antipsychotics and some 5-HT₂ receptor antagonists, display moderate to high affinity for both recombinant and functional 5-HT₇ receptors.

Functionally, the 5-HT₇ receptor has been implicated in regulation of circadian rhythms in mammals (Lovenberg, T.W. et al. *Neuron*, 1993, 11:449-458 “*A novel adenylyl cyclase-activating serotonin receptor (5-HT₇) implicated in the regulation of circadian rhythms*”). It is known that disruption of circadian rhythms is related to a number of CNS disorders including depression, seasonal affective disorder, sleep disorders, shift worker syndrome and jet lag among others.

Distribution and early pharmacological data also suggest that the 5-HT₇ receptor is involved in the vasodilatation of blood vessels. This has been demonstrated *in vivo* (Terrón, J.A., *Br J Pharmacol*, 1997, 121:563-571 “*Role of 5-HT₇ receptors in the long lasting hypotensive response induced by 5-hydroxytryptamine in the rat*”). Thus selective 5-HT₇ receptor agonists have a potential as novel hypertensive agents.

The 5-HT₇ receptor has also been related with the pathophysiology of migraine through smooth muscle relaxation of cerebral vessels (Schoeffter, P. et al., 1996, *Br J Pharmacol*, 117:993-994; Terrón, J.A., 2002, *Eur. J. Pharmacol.*, 439:1-11 “*Is the 5-HT₇ receptor involved in the pathogenesis and prophylactic treatment of migraine?*”). In a similar manner, involvement of 5-HT₇ in intestinal and colon tissue smooth muscle relaxation makes this receptor a target for the treatment of irritable bowel syndrome (De Ponti, F. et al. , 2001, *Drugs*, 61:317-332 “*Irritable bowel syndrome. New agents targeting serotonin receptor subtypes*”). Recently, it has also been related to urinary incontinence (*British J. of Pharmacology*, Sept. 2003, 140(1) 53-60: “*Evidence for the involvement of central 5HT-7 receptors in the micurition reflex in anaeshetized female rats*”).

In view of the potential therapeutic applications of agonists or antagonists of the 5HT₇ receptor, a great effort has been directed to find selective ligands. Despite intense research efforts in this area, very few compounds with selective 5-HT₇ antagonist activity have been reported (Wesolowska, A., *Polish J. Pharmacol.*, 2002, 54: 327-341, “*In the search for selective ligands of 5-HT₅, 5-HT₆ and 5-HT₇ serotonin receptors*”).

WO 97/48681 discloses sulfonamide derivatives, which are 5-HT₇ receptor antagonists, for the treatment of CNS disorders. The sulphur atom is linked to an aromatic

group and to a N-containing heterocyclic group, optionally containing a further heteroatom selected from oxygen or sulphur.

WO 97/29097 describes sulfonamide derivatives for the treatment of disorders in which antagonism of the 5-HT₇ receptor is beneficial. The sulphur atom is linked to an aromatic group and to a C₁-C₆ alkyl substituted N atom.

WO97/49695 describes further sulfonamide derivatives in which the N linked to the sulphur atom is also fully substituted, for example forming part of a piperidine.

WO 03/048118 describes another group of 5HT₇ receptor antagonists. In this case aryl and heteroaryl sulfonamide derivatives wherein the sulfonamide group is a substituent on a cycloalkane or cycloalkene ring which additionally bears an amino substituent. The N linked to sulphur atom is fully substituted.

WO99/24022 discloses tetrahydroisoquinoline derivatives for use against CNS disorders and binding to serotonin receptors, in particular 5-HT₇.

WO 00/00472 refers to compounds which are 5-HT₇ receptor antagonists. The compounds contain a N-containing fused heterocycle such as tetrahydroisoquinoline.

EP 21580 and EP 76072 describe sulfonamide compounds having antiarrhythmic activity, corresponding to the formula R₂N(CH₂)_n-NH-SO₂R₁, 5-HT₇ activity is not mentioned.


There is still a need to find compounds that have pharmacological activity towards the receptor 5-HT₇, being both effective and selective, and having good "drugability" properties, i.e. good pharmaceutical properties related to administration, distribution, metabolism and excretion.

SUMMARY OF THE INVENTION

We have now found a family of structurally distinct class of sulfonamide compounds which are particularly selective inhibitors of the 5-HT₇ receptor. The

compounds present a tetrahydroisoquinoline moiety, linked through a straight alkylene chain of a certain size with a sulfonamide moiety. We have found that when the N of the sulfonamide is a secondary amine and the linker has 4, 5 or 6 $-\text{CH}_2-$ units the compounds display IC_{50} values in the nM range (>10 nM) at human 5-HT₇ receptors and exhibit at least 30-fold selectivity for these receptors vs 5-HT_{1A}, 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C}, 5-HT₃, 5-HT₄, 5-HT_{5A}, D₁, D₂, D₃, D₄, adrenergic α _{1A}, α _{1B}, β ₁, and β ₂ receptors.

In one aspect the invention is directed to a compound of the formula I:



wherein

W is a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R_1 , R_2 , R_3 , R_4 , R_5 , R_6 and R_7 are each independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, $-\text{COR}_8$, $-\text{C}(\text{O})\text{OR}_8$, $-\text{C}(\text{O})\text{NR}_8\text{R}_9$, $-\text{C}=\text{NR}_8$, $-\text{CN}$, $-\text{OR}_8$, $-\text{OC}(\text{O})\text{R}_8$, $-\text{S}(\text{O})_t\text{R}_8$, $-\text{NR}_8\text{R}_9$, $-\text{NR}_8\text{C}(\text{O})\text{R}_9$, $-\text{NO}_2$, $-\text{N}=\text{CR}_8\text{R}_9$ or halogen, wherein

t is 1, 2 or 3;

R_8 and R_9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, halogen;

n is 4, 5 or 6;

or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.

In one embodiment n is preferably 4 or 5, most preferably n is 4.

It is preferred that W is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, preferably substituted or unsubstituted phenyl. Good results were obtained when W is alkyl or halo substituted phenyl.

It is preferred that in the tetrahydroisoquinoline moiety R₅, R₆ and R₇ are H.

In one embodiment R₁ and R₄ are also H.

Good results are obtained when R₂ and R₃ are alkoxy, in particular methoxy.

In another aspect the invention is directed to a pharmaceutical composition which comprises a compound as above defined or a pharmaceutically acceptable salt, enantiomer, prodrug or solvate thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

In a further aspect the invention is directed to the use of a compound as defined above in the manufacture of a medicament for the treatment of a 5-HT₇ mediated disease or condition, i.e. diseases caused by failures in central and peripheral serotonin-controlling functions, such as pain, sleep disorder, shift worker syndrome, jet lag, depression, seasonal affective disorder, migraine, anxiety, psychosis, schizophrenia, cognition and memory disorders, neuronal degeneration resulting from ischemic events, cardiovascular diseases such as hypertension, irritable bowel syndrome, inflammatory bowel disease, spastic colon or urinary incontinence.

DETAILED DESCRIPTION OF THE INVENTION

The typical compounds of this invention effectively and selectively inhibit the 5-HT₇ receptor without inhibition of other 5-HT receptors such as 5-HT_{1A}, 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C}, 5-HT₃, 5-HT₄, 5-HT_{5A}, D₁, D₂, D₃, D₄, adrenergic α _{1A}, α _{1B}, α _{2B}, β ₁, and β ₂ receptors, Tachykinin NK-1 opiate, GABA, estrogen, glutamate, adenosine, nicotinic, muscarinic receptors and calcium, potassium and sodium channels and neurotransmitter transporters (serotonin, dopamine, norepinephrine, GABA).

In the above definition of compounds of formula (I) the following terms have the meaning indicated:

"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms, containing no saturation, having one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e. g., methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc. Alkyl radicals may be optionally substituted by one or more substituents such as a aryl, halo, hydroxy, alkoxy, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro, mercapto, alkylthio, etc. If substituted by aryl we have an "Aralkyl" radical, such as benzyl and phenethyl.

"Alkenyl" refers to an alkyl radical having at least 2 C atoms and having one or more unsaturated bonds.

"Cycloalkyl" refers to a stable 3-to 10-membered monocyclic or bicyclic radical which is saturated or partially saturated, and which consist solely of carbon and hydrogen atoms, such as cyclohexyl or adamantyl. Unless otherwise stated specifically in the specification, the term "cycloalkyl" is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents such as alkyl, halo, hydroxy, amino, cyano, nitro, alkoxy, carboxy, alkoxycarbonyl, etc.

"Aryl" refers to single and multiple ring radicals, including multiple ring radicals that contain separate and/or fused aryl groups. Typical aryl groups contain from 1 to 3 separated or fused rings and from 6 to about 18 carbon ring atoms, such as phenyl, naphthyl, indenyl, fenanthryl or anthracyl radical. The aryl radical may be optionally substituted by one or more substituents such as hydroxy, mercapto, halo, alkyl, phenyl, alkoxy, haloalkyl, nitro, cyano, dialkylamino, aminoalkyl, acyl, alkoxycarbonyl, etc.

"Heterocyclyl" refers to a stable 3-to 15 membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, preferably a 4-to 8-membered ring with one or more heteroatoms, more preferably a 5-or 6-membered ring with one or more heteroatoms. For the purposes of this invention, the heterocycle may be a monocyclic, bicyclic or tricyclic

ring system, which may include fused ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidised; the nitrogen atom may be optionally quaternized ; and the heterocyclyl radical may be partially or fully saturated or aromatic. Examples of such heterocycles include, but are not limited to, azepines, benzimidazole, benzothiazole, furan, isothiazole, imidazole, indole, piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran, coumarine, morpholine; pyrrole, pyrazole, oxazole, isoxazole, triazole, imidazole, etc.

"Alkoxy" refers to a radical of the formula -ORa where Ra is an alkyl radical as defined above, e. g., methoxy, ethoxy, propoxy, etc.

"Alkoxy carbonyl" refers to a radical of the formula -C(O)ORa where Ra is an alkyl radical as defined above, e. g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, etc.

"Alkylthio" refers to a radical of the formula -SRa where Ra is an alkyl radical as defined above, e. g., methylthio, ethylthio, propylthio, etc.

"Amino" refers to a radical of the formula -NH₂, -NHRa or -NRaRb, optionally quaternized.

"Halo" or "hal" refers to bromo, chloro, iodo or fluoro.

References herein to substituted groups in the compounds of the present invention refer to the specified moiety that may be substituted at one or more available positions by one or more suitable groups, e. g., halogen such as fluoro, chloro, bromo and iodo ; cyano; hydroxyl ; nitro ; azido ; alkanoyl such as a C1-6 alkanoyl group such as acyl and the like; carboxamido; alkyl groups including those groups having 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms and more preferably 1-3 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those moieties having one or more thioether linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms;

alkylsulfinyl groups including those moieties having one or more sulfinyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms ; alkylsulfonyl groups including those moieties having one or more sulfonyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; carbocyclic aryl having 6 or more carbons, particularly phenyl or naphthyl and aralkyl such as benzyl. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.

Particular individual compounds of the invention include the compounds 1-338 in the examples, either as salts or as free bases.

In an embodiment the tetrahydroisoquinoline in the compounds of formula I above is not substituted, R_1 to R_7 are all H. Good activity results are obtained with such compounds.

In another embodiment R_2 and R_3 are alkoxy, preferably methoxy and the rest of the substituents of the tetrahydroisoquinoline (R_1 and R_4 to R_7) are H. In this case it appears that the selectivity is improved.

In another embodiment the group W linked to the sulfonamide is aromatic, such as substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, preferably substituted or unsubstituted phenyl. Good results were obtained when W is alkyl, alkoxy or halo substituted phenyl. In particular halo substituted phenyl, having one or more halo substituents being the same or different are preferred.

In another embodiment it is important that n is 4, best results were obtained with this length of the chain linking the tetrahydroisoquinoline and the sulfonamide.

The above embodiments and preferences for W, R_1 to R_7 and n can be combined to give further preferred compounds.

Representative compounds of the above embodiments which are preferred are Naphthalene-2-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride; N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride; 5-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,4-difluoro-benzenesulfonamide; 2-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride; N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-difluoro-benzenesulfonamide hydrochloride; N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2,4,5-trifluoro-benzenesulfonamide hydrochloride; 2-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4,5-difluoro-benzenesulfonamide hydrochloride; 2-Bromo-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4,6-difluoro-benzenesulfonamide hydrochloride; N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-3-methyl-benzenesulfonamide hydrochloride; 4-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-dimethyl-benzenesulfonamide hydrochloride; N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-dimethoxy-benzenesulfonamide hydrochloride or 2-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride. Although the hydrochloride salts are listed, other salts or the free bases also form part of this group of preferred compounds.

Unless otherwise stated, the compounds of the invention are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a ^{13}C - or ^{14}C -enriched carbon or ^{15}N -enriched nitrogen are within the scope of this invention.

The term "pharmaceutically acceptable salts, solvates, prodrugs" refers to any pharmaceutically acceptable salt, ester, solvate, or any other compound which, upon administration to the recipient is capable of providing (directly or indirectly) a compound as described herein. However, it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the invention since those may be useful in the preparation of pharmaceutically acceptable salts. The preparation of salts, prodrugs and derivatives can be carried out by methods known in the art.

For instance, pharmaceutically acceptable salts of compounds provided herein are synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts are, for example, prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent or in a mixture of the two. Generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. Examples of the acid addition salts include mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate, and organic acid addition salts such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulphonate and p-toluenesulphonate. Examples of the alkali addition salts include inorganic salts such as, for example, sodium, potassium, calcium, ammonium, magnesium, aluminium and lithium salts, and organic alkali salts such as, for example, ethylenediamine, ethanolamine, N,N-dialkylmethylethanolamine, triethanolamine, glucamine and basic aminoacids salts.

Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.

Any compound that is a prodrug of a compound of formula (I) is within the scope of the invention. The term "prodrug" is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. Such derivatives would readily occur to those skilled in the art, and include, depending on the functional groups present in the molecule and without limitation, the following derivatives of the present compounds: esters, amino acid esters, phosphate esters, metal salts sulfonate esters, carbamates, and amides.


The compounds of the invention may be in crystalline form either as free compounds or as solvates and it is intended that both forms are within the scope of the present invention. Methods of solvation are generally known within the art. Suitable

solvates are pharmaceutically acceptable solvates. In a particular embodiment the solvate is a hydrate.


The compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. Purity levels for the drug substance are preferably above 50%, more preferably above 70%, most preferably above 90%. In a preferred embodiment it is above 95% of the compound of formula (I), or of its salts, solvates or prodrugs.

The compounds of the present invention represented by the above described formula (I) may include enantiomers depending on the presence of chiral centres or isomers depending on the presence of multiple bonds (e.g. Z, E). The single isomers, enantiomers or diastereoisomers and mixtures thereof fall within the scope of the present invention.

The compounds of formula (I) defined above can be obtained by available synthetic procedures. For example, they can be prepared by the coupling of a compound of Formula (II):



in which R1-R7 and n are as defined in Formula (I), with a compound of Formula (III):




in which W is as defined in Formula (I) and X is an halogen, typically Cl.

The reaction of compounds of formulas (II) and (III) is preferably carried out in an aprotic solvent, but not limited to, such as dichloromethane in the presence of an organic base, such as diisopropylethylamine or triethylamine.

Compounds of Formula (III) are commercially available or can be prepared by conventional methods.


Compounds of Formula (II) can be prepared from compounds of Formula (IV) using the reactions and techniques described below. Compounds of Formula (IV) are commercially available or may be prepared according to known methods.



The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations. The functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a selection of a particular process scheme over another in order to obtain the desired compound of the invention. Preferred methods included, but are not limited to, those described below. References for cited described methods are incorporated.

Compounds of Formula (II) can be prepared by alkylation as shown in Scheme 1.

Scheme 1




In the first step, the amine of Formula (IV) is allowed to react with a commercially available *N*-(*n*-haloalkyl)phthalimide (1-1) in the presence of an appropriate base and solvent. Useful bases include, but are not limited to, metal carbonates such as K₂CO₃ or Cs₂CO₃, metal hydroxides, hindered alkoxides or tertiary organic amines.

Typical solvents include polar aprotic liquids such as DMF or THF, or protic liquids such as alcohols. The use of butanol or xylene have been previously described (*J. Med. Chem.* **1996**, 39(5), 1125-1129, *J. Med. Chem.* **1999**, 42(4), 730-741) but the yield is improved, (from 50% to 90%), with the use of *N,N*-dimethylformamide and K₂CO₃ as the base.

In a second step, the hydrazinolysis of the alkylated compound 1-2 using hydrazine in a polar protic solvent, such as ethanol, and hydrochloric acid gives the desired compound of Formula (II).

A similar route to compounds of Formula (II) is illustrated in Scheme 2.

Scheme 2




The acylation of compounds of Formula (IV) with carboxyalkylphthalimides derivatives (2-1), instead of the alkylation with *N*-(*n*-haloalkyl)phthalimides (1-1), may be convenient in some cases. When X is a Cl, the base used for acylation could be a tertiary organic amine such as triethylamine or *N,N*-diisopropylethylamine and the hydrazinolysis can be performed as cited in Scheme 1. When X is an OH, a coupling reagent must be used for the activation of carboxy group. Many coupling reagents are known in the literature to form amide bonds from carboxylic acids and amines, including DCC, HBTU, TBTU, BOP, PyBOP, etc. Appropriate bases for such coupling reactions include tertiary amines such as *N,N*-diisopropylethylamine, triethylamine, etc. The activated species are usually not isolated, but are allowed to react *in situ* with the amine partner (IV).

After the hydrazinolysis of phthalimide 2-2, the reduction of the amide intermediate 2-3 may be performed with a reducing agent, such as borane or lithium aluminum hydride

in appropriate solvent, typically THF (*J. Med. Chem.* **1987**, 30, 1186-1193, *Anales Química*, **1983**, 80, 283-290).

A similar method to compounds of Formula (II) is illustrated in Scheme 3.

Scheme 3




A reductive amination with phtalimidoalkylaldehydes (3-1), following by hydrazinolysis may also be performed. Condensation of the amine (IV) with aldehydes 3-1 can be performed in the presence of an hydride, such as sodium triacethoxyborohydride $NaBH(OAc)_3$ or sodium cyanoborhydride ($NaBH_4CN$) (*Bioorg. Med. Chem. Lett.* **1999**, 9, 179-184). Phtalimide intermediate 3-2 is treated as is described in Schemes 1 and 2 in order to obtain the desired compound of Formula (II).

In all these Schemes, other protecting groups for the nitrogen atom, instead of the phtalimide, may be used. Some examples include other cyclic imide derivatives, such as maleimides or succinimides, a variety of carbamates, such as BOC; Fmoc, etc. a variety of amides, such as acetamides, and alkyl and aryl amine derivatives, such as *N*-benzyl or *N*-

allyl. Additional examples of Nitrogen protecting groups can be found in reference books such as Greene and Wuts' "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999.

An alternate sequence for the preparation of some compounds of Formula (II) is illustrated in Scheme 4.

Scheme 4



Compounds of Formula (II) can be prepared in a sequential way by treatment of a dialkylating agent (4-1) with the corresponding amine (IV) in the presence of a base in an appropriate solvent, followed by the alkylation of another amine (4-2).

Examples of useful alkylating agents (4-1) are those where Y is a good to excellent leaving group, such as Br, I, aryl or alkylsulfonate, etc. and X is a good leaving group,


such as Br or Cl. Useful bases include, but are not limited to, metal carbonates such as K_2CO_3 or Cs_2CO_3 , metal hydroxides, hindered alkoxides or tertiary organic amines.

Typical solvents include polar aprotic liquids such as DMF or THF, or protic liquids such as alcohols. The rate of the second alkylation may be enhanced, particularly when X is Cl, by the addition of a catalytic amount of an iodide salt, such as NaI or KI.

The required alkylating agents (4-1) are generally commercially available.

Where convenient, compounds of Formula (II) can be prepared as shown in Scheme 5.

Scheme 5




The alkylation of compounds of Formula (IV) with commercially available haloalkyl nitriles (5-1) can be performed in the presence of a variety of bases and solvents cited in schemes above. For the reduction of the cyano group of 5-2, common reducing agents, such as $LiAlH_4$ in THF, can be used. A catalytic hydrogenation with Pd/C in

ethanol is also possible (*Bioorg. Med. Chem. Lett.* **2004**, 14, 195-202, *J. Med. Chem.* **1999**, 42(4), 730-741).

In some cases, an acylation with carboxynitriles to form an amide is preferred instead of the alkylation with the corresponding haloalkylnitriles (Scheme 6).

Scheme 6




The acylation with compounds 6-1, where X is a good leaving group, such as I, Br, aryl or alkylsulphonate, is carried out in the presence of an appropriate base and solvent, which were described in schemes above. The reduction of cyano and keto group of 6-2 can be performed simultaneously in the presence of an excess of a reducing agent such as LiAlH₄ or borane. When X is OH, a coupling reagent must also be used for the activation of carboxy group. The coupling reagents used are the same as are cited in Scheme 2.

Scheme 6 is also possible when X is an H. Reductive amination is carried out by a condensation of amine of Formula (IV) with aldehyde 6-1 in appropriate base and solvent,

to form an imine or enamine intermediate, followed by a reduction with a reducing agent, such as an hydride.

An alternate sequence for the preparation of some compounds of Formula (II) is illustrated in Scheme 7.

Scheme 7



Amines of Formula (IV) may be alkylated with haloalkylamides 7-1 in an appropriate solvent and base, the same as are cited in Schemes above. Intermediate (7-2) may be reduced in the presence of an hydride, such as $LiAlH_4$ or borane.

The obtained reaction products may, if desired, be purified by conventional methods, such as crystallisation, chromatography and trituration. Where the above described processes for the preparation of compounds of the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. If there are chiral centers the compounds may be prepared in

racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.

One preferred pharmaceutically acceptable form is the crystalline form, including such form in pharmaceutical composition. In the case of salts and solvates the additional ionic and solvent moieties must also be non-toxic. The compounds of the invention may present different polymorphic forms, it is intended that the invention encompasses all such forms.

Another aspect of this invention relates to a method of treating or preventing an 5-HT₇ mediated disease which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutical composition thereof. Among the 5-HT₇ mediated diseases that can be treated are diseases caused by failures in central and peripheral serotonin-controlling functions, such as pain, sleep disorder, shift worker syndrome, jet lag, depression, seasonal affective disorder, migraine, anxiety, psychosis, schizophrenia, cognition and memory disorders, neuronal degeneration resulting from ischemic events, cardiovascular diseases such as hypertension, irritable bowel syndrome, inflammatory bowel disease, spastic colon or urinary incontinence.

The present invention further provides pharmaceutical compositions comprising a compound of this invention, or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomers thereof together with a pharmaceutically acceptable carrier, adjuvant, or vehicle, for administration to a patient.

Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules etc.) or liquid (solutions, suspensions or emulsions) composition for oral, topical or parenteral administration.

In a preferred embodiment the pharmaceutical compositions are in oral form, either solid or liquid. Suitable dose forms for oral administration may be tablets, capsules, syrups or solutions and may contain conventional excipients known in the art such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine;

tableting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulfate.

The solid oral compositions may be prepared by conventional methods of blending, filling or tableting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art. The tablets may for example be prepared by wet or dry granulation and optionally coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

The pharmaceutical compositions may also be adapted for parenteral administration, such as sterile solutions, suspensions or lyophilized products in the appropriate unit dosage form. Adequate excipients can be used, such as bulking agents, buffering agents or surfactants.

The mentioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopoeias and similar reference texts.

Administration of the compounds or compositions of the present invention may be by any suitable method, such as intravenous infusion, oral preparations, and intraperitoneal and intravenous administration. Oral administration is preferred because of the convenience for the patient and the chronic character of the diseases to be treated.

Generally an effective administered amount of a compound of the invention will depend on the relative efficacy of the compound chosen, the severity of the disorder being treated and the weight of the sufferer. However, active compounds will typically be administered once or more times a day for example 1, 2, 3 or 4 times daily, with typical total daily doses in the range of from 0.1 to 1000 mg/kg/day.

The compounds and compositions of this invention may be used with other drugs to provide a combination therapy. The other drugs may form part of the same composition, or

be provided as a separate composition for administration at the same time or at different time.

The following examples are given only as further illustration of the invention, they should not be taken as a definition of the limits of the invention.

EXAMPLES

The starting materials of general formula (II) were prepared by means of conventional organic chemistry methods known to those skilled in the art. The preparation of some of the intermediates of general formulas (II) and (IV) is shown below:


Example A:

The starting materials of general formulas (IV) were prepared by means of conventional organic chemistry methods known to those skilled in the art.

Synthesis of a compound of general formula (IV)

7-Nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride.

This compound is described in the literature for Buolamwini et al. *J.Med.Chem.* **2003**, 46, 831-837, which are hereby incorporated by reference and form part of the disclosure.



A cold solution of 1,2,3,4-tetrahydroisoquinoline (13,3 g, 0.1 mol) in concentrated sulfuric acid (50 mL) was treated with potassium nitrate (11.12 g, 1,1 mol) in small portions, keeping the temperature below 5 °C. The reaction was left overnight at room temperature and poured onto ice. The resulting solution was basified with ammonium hydroxide, extracted with CH₂Cl₂, dried and evaporated to dryness in vacuo. The crude was dissolved in 100 mL ethanol. A 2,8 M solution of hydrogen chloride in ethanol (40 mL) was then added. The precipitate formed was collected by filtration and crystallized from methanol to give the product (10,30 g, 48 % yield) as a white solid.


Melting point: 268-270 °C.

IR cm^{-1} (KBr) : 2944, 2764, 1589, 1523, 1429, 1345, 1090.

^1H NMR (300 MHz, DMSO- d_6) δ ppm : 3.13 (t, $J=6.15$ Hz, 2 H), 3.35 (t, $J=6.22$ Hz, 2 H), 4.35 (s, 2 H), 7.50 (d, $J=8.49$ Hz, 1 H), 8.08 (dd, $J=8.49, 2.49$ Hz, 1 H), 8.19 (d, $J=2.34$ Hz, 1 H), 9.96 (s, 2 H)

Example B:

Synthesis of a compound of general formula (II)



a) 2-(4-*N*-phthalimidobutyl)- 7-nitro-1,2,3,4-tetrahydroisoquinoline.

A mixture of 7-nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride (9,87 g, 0.046 mol), *N*-(4-Bromobutyl)phthalimide (12,97 g, 0.046 mol), potassium carbonate (25,43 g, 0.184 mol) in dry *N,N*-dimethylformamide (150 mL), was stirred overnight at room temperature. The mixture was vacuum concentrated and the residue was dissolved in water (150 mL) and extracted with ethyl acetate (3 x 50 mL), washed with water, the organic layer was dried and evaporated to give the product (16,58 g, 95% yield) which was used without further purification.

^1H NMR (300 MHz, DMSO- D_6) δ ppm 1.64 (m, 2 H), 1.79 (m, 2 H), 2.60 (m, 2 H), 2.78 (m, 2 H), 2.96 (m, 2 H), 3.72 (m, 4 H), 7.23 (m, 1 H), 7.71 (m, 2 H), 7.79 (m, 3 H), 8.01 (m, 1 H)

b) 2-(4-aminobutyl)-7-nitro-1,2,3,4-tetrahydroisoquinoline dihydrochloride.

A solution of 2-(4-*N*-Phtalimidobutyl)- 7-nitro-1,2,3,4-tetrahydroisoquinoline (16,30 g, 0,043 mol) and hydrazine hydrate (13,4 mL, 0.43 mol) in ethanol (350 mL) was refluxed for 1 h. The reaction mixture was cooled down and treated with an additional amount of ethanol (350

mL) and concentrated HCl (45 mL). Then the reaction mixture was refluxed for 4 h and left overnight in a refrigerator. The precipitate was filtered off, and the solvent was evaporated. The residue was basified with ammonium hydroxide (120 mL) and was extracted with CH₂Cl₂ (3 x 120 mL), the organic layer was dried over Na₂SO₄, and evaporated to dryness. The crude was dissolved in 100 mL ethanol. A 2,8 M solution of hydrogen chloride in ethanol (35 mL) was then added. The precipitate formed was collected by filtration and crystallized from methanol and 2-propanol to give the product (8.59 g, 62 % yield) as a brown solid.

Melting point: 220-224°C.


IR cm⁻¹(KBr) : 3024, 2934, 2561, 1529, 1344, 1095, 740.

¹H NMR (300 MHz, DMSO-d₆) δ ppm : 1.66 (m, 2 H), 1.89 (m, 2 H), 2.83 (m, 2 H), 3.21 (m, 3 H), 3.32 (m, 2 H), 3.72 (m, 1 H), 4.38 (dd, *J*=15.96, 7.61 Hz, 1 H), 4.68 (d, *J*=14.50 Hz, 1 H), 7.55 (d, *J*=8.35 Hz, 1 H), 8.05 (s, 2 H), 8.14 (m, 2 H), 11.51 (s, 1 H).

Example C:

The compounds of general formula (I) were prepared by the coupling of a compound of formula (II) with a compound of formula (III) by means of conventional organic chemistry methods known to those skilled in the art.

Naphthalene-1-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]amide hydrochloride



A solution of 2-(4-aminobutyl)-1,2,3,4-tetrahydroisoquinoline dihydrochloride (272 mg, 1 mmol), *N,N*-diisopropylethylamine (517 mg, 4 mmol) in CH₂Cl₂ (10 mL), was added naphthalene-1-sulfonyl chloride (238 mg, 1.05 mmol) and was stirred overnight at room temperature. The resulting solution was washed with water (3 x 15 mL) and dried





over Na₂SO₄, and evaporated to dryness. The free base was dissolved in 2-propanol (5 mL). A 2,8 M solution of hydrogen chloride in ethanol (0.40 mL) was then added. The product was crystallized and collected by filtration, and vacuum dried to give a white solid (310 mg, 72%).






Melting point: 203-206°C.





IR cm⁻¹(KBr) : 3087, 2941, 2679, 2601, 1446, 1420, 1314, 1153, 1132, 801, 775, 747.





¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.38 (m, 2 H), 1.66 (d, J=6.77 Hz, 2 H), 2.81 (q, J=6.47 Hz, 2 H), 2.91 (s, 1 H), 2.99 (d, J=9.34 Hz, 2 H), 3.18 (m, 2 H), 3.52 (d, J=6.41 Hz, 1 H), 4.12 (m, 1 H), 4.36 (m, 1 H), 7.21 (m, 4 H), 7.69 (m, 3 H), 8.10 (m, 3 H), 8.23 (d, J=8.24 Hz, 1 H), 8.66 (d, J=8.61 Hz, 1 H), 11.02 (s, 1 H).





The spectroscopic data for the identification of some of the sulfonamides compounds of the invention having general formula (I), prepared analogously to the methods described in the above examples, are shown in the following table 1:





N°	STRUCTURE	Autonom	¹ H-NMR	MS (APCI (M+H) ⁺)
1		Naphthalene-1-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.38 (m, 2 H), 1.66 (d, J=6.77 Hz, 2 H), 2.81 (q, J=6.47 Hz, 2 H), 2.91 (s, 1 H), 2.99 (d, J=9.34 Hz, 2 H), 3.18 (m, 2 H), 3.52 (d, J=6.41 Hz, 1 H), 4.12 (m, 1 H), 4.36 (m, 1 H), 7.21 (m, 4 H), 7.69 (m, 3 H), 8.10 (m, 3 H), 8.23 (d, J=8.24 Hz, 1 H), 8.66 (d, J=8.61 Hz, 1 H), 11.02 (s, 1 H)	395
2		Naphthalene-2-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.72 (s, 2 H), 2.79 (d, J=6.41 Hz, 2 H), 2.96 (m, 1 H), 3.09 (s, 2 H), 3.20 (s, 2 H), 3.59 (s, 1 H), 4.17 (m, 1 H), 4.43 (m, 1 H), 7.21 (m, 4 H), 7.68 (m, 2 H), 7.82 (m, 2 H), 8.04 (d, J=8.42 Hz, 1 H), 8.15 (m, 2 H), 8.43 (s, 1 H), 10.64 (s, 1 H)	395
3		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-3-trifluoromethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.76 (d, J=6.41 Hz, 2 H), 2.79 (q, J=6.59 Hz, 2 H), 3.00 (m, 1 H), 3.11 (s, 2 H), 3.23 (m, 2 H), 3.62 (d, J=7.14 Hz, 1 H), 4.20 (m, 1 H), 4.45 (m, 1 H), 7.23 (m, 4 H), 7.87 (t, J=7.78 Hz, 1 H), 8.07 (m, 4 H), 10.78 (s, 1 H)	413
4		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-4-methoxybenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.43 (m, 2 H), 1.76 (m, 2 H), 2.72 (q, J=6.59 Hz, 2 H), 2.98 (m, 1 H), 3.10 (s, 2 H), 3.22 (m, 2 H), 3.61 (s, 1 H), 3.79 (m, 3 H), 4.21 (dd, J=15.11, 7.42 Hz, 1 H), 4.45 (m, 1 H), 7.12 (m, 2 H), 7.22 (m, 4 H), 7.57 (t, J=5.86 Hz, 1 H), 7.73 (m, 2 H), 10.81 (s, 1 H)	375





5		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.45 (m, 2 H), 1.75 (m, 2 H), 2.76 (q, J=6.71 Hz, 2 H), 2.98 (m, 1 H), 3.10 (s, 2 H), 3.18 (s, 1 H), 3.26 (s, 1 H), 3.60 (m, 1 H), 4.20 (m, 1 H), 4.45 (d, J=15.75 Hz, 1 H), 7.23 (m, 4 H), 7.62 (m, 3 H), 7.77 (m, 3 H), 10.71 (s, 1 H)	345
6		4-(4-Bromo-phenoxy)-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.43 (m, 2 H), 1.75 (m, 2 H), 2.75 (q, J=6.23 Hz, 2 H), 3.01 (m, 1 H), 3.11 (s, 2 H), 3.23 (m, 2 H), 3.61 (s, 1 H), 4.21 (m, 1 H), 4.46 (m, 1 H), 7.13 (m, 5 H), 7.24 (d, J=5.68 Hz, 2 H), 7.61 (m, 2 H), 7.71 (m, 1 H), 7.79 (d, J=6.96 Hz, 2 H), 10.78 (s, 1 H)	515
7		Thiophene-2-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.51 (m, 2 H), 1.76 (m, 2 H), 2.80 (m, 2 H), 3.00 (m, 1 H), 3.13 (m, 2 H), 3.25 (m, 2 H), 3.61 (s, 1 H), 4.25 (m, 1 H), 4.48 (m, 1 H), 7.23 (m, 5 H), 7.58 (dd, J=2.93, 1.65 Hz, 1 H), 7.90 (m, 2 H), 10.48 (s, 1 H)	351
8		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-C-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-yl)-methanesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 0.83 (m, 3 H), 1.02 (m, 4 H), 1.36 (m, 1 H), 1.51 (m, 3 H), 1.82 (m, 2 H), 1.91 (m, 1 H), 2.01 (m, 1 H), 2.33 (m, 2 H), 3.01 (m, 2 H), 3.17 (m, 3 H), 3.31 (m, 2 H), 3.71 (m, 1 H), 4.27 (dd, J=15.66, 8.15 Hz, 1 H), 4.50 (d, J=14.65 Hz, 1 H), 7.09 (m, 1 H), 7.24 (m, 4 H), 10.19 (s, 1 H)	419
9		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2-nitro-benzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.48 (m, 2 H), 1.74 (m, 2 H), 2.94 (m, 2 H), 3.04 (m, 1 H), 3.14 (m, 2 H), 3.24 (m, 2 H), 3.62 (d, J=4.39 Hz, 1 H), 4.22 (m, 1 H), 4.46 (m, 1 H), 7.22 (m, 4 H), 7.86 (m, 2 H), 7.98 (m, 2 H), 8.24 (m, 1 H), 10.68 (s, 1 H)	390





10		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-3-nitro-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.45 (m, 2 H), 1.72 (m, 2 H), 2.79 (m, 2 H), 3.02 (s, 1 H), 3.10 (m, 2 H), 3.23 (m, 2 H), 3.60 (m, 1 H), 4.21 (m, 1 H), 4.45 (m, 1 H), 7.23 (m, 4 H), 7.92 (m, 1 H), 8.11 (m, 1 H), 8.23 (m, 1 H), 8.49 (m, 2 H), 10.52 (s, 1 H)	390
11		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-4-methanesulfonyl-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.46 (m, J=7.12 Hz, 2 H), 1.76 (m, 2 H), 2.81 (q, J=6.59 Hz, 2 H), 2.98 (m, 1 H), 3.10 (m, 2 H), 3.23 (m, 2 H), 3.30 (s, 3H), 3.60 (m, 1 H), 4.19 (m, 1 H), 4.44 (m, 1 H), 7.23 (m, 4 H), 8.10 (m, 5 H), 10.91 (s, 1 H)	423
12		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-4-methyl-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.75 (m, 2 H), 2.36 (s, 3 H), 2.72 (q, J=6.59 Hz, 2 H), 2.97 (m, 1 H), 3.08 (d, J=5.31 Hz, 2 H), 3.22 (m, 2 H), 3.60 (s, 1 H), 4.21 (m, 1 H), 4.44 (d, J=15.20 Hz, 1 H), 7.23 (m, 4 H), 7.39 (d, J=7.87 Hz, 2 H), 7.65 (m, 3 H), 10.75 (s, 1 H)	359
13		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-4-fluoro-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.46 (m, 2 H), 1.75 (d, J=7.14 Hz, 2 H), 2.76 (q, J=6.53 Hz, 2 H), 2.99 (m, 1 H), 3.10 (s, 2 H), 3.23 (m, 2 H), 3.60 (s, 1 H), 4.19 (m, 1 H), 4.43 (m, 1 H), 7.23 (m, 4 H), 7.44 (m, 2 H), 7.84 (m, 3 H), 10.81 (s, 1 H)	363





14		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2,4-dimethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.43 (m, 2 H), 1.72 (m, 2 H), 2.31 (s, 3 H), 2.52 (s, 3 H), 2.74 (d, J=6.23 Hz, 2 H), 2.96 (m, 1 H), 3.08 (m, 2 H), 3.24 (m, 2 H), 3.60 (m, 1 H), 4.20 (m, 1 H), 4.43 (m, 1 H), 7.22 (m, 6 H), 7.67 (m, 2 H), 10.87 (s, 1 H)	373
15		2-Naphthalen-1-yl-ethanesulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.54 (m, 2 H), 1.84 (m, 2 H), 3.03 (m, 3 H), 3.17 (m, 4 H), 3.37 (m, 2 H), 3.42 (m, 2 H), 3.66 (d, J=11.54 Hz, 1 H), 4.25 (m, 1 H), 4.48 (m, 1 H), 7.22 (m, 4 H), 7.42 (m, 3 H), 7.56 (m, 2 H), 7.82 (dd, J=6.87, 2.84 Hz, 1 H), 7.93 (d, J=1.10 Hz, 1 H), 8.01 (d, J=8.24 Hz, 1 H), 10.59 (s, 1 H)	423
16		5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.47 (m, 2 H), 1.71 (d, J=7.14 Hz, 2 H), 2.60 (s, 3 H), 2.94 (m, 3 H), 3.11 (m, 3 H), 3.23 (d, J=8.24 Hz, 1 H), 3.60 (d, J=10.99 Hz, 1 H), 4.20 (dd, J=15.38, 7.87 Hz, 1 H), 4.44 (m, 1 H), 7.20 (m, 4 H), 7.53 (dd, J=8.79, 2.01 Hz, 1 H), 8.02 (m, 2 H), 8.22 (m, 1 H), 10.07 (s, 1 H)	449
17		4-Acetyl-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) □ ppm 1.44 (m, 2 H), 1.72 (m, 2 H), 2.59 (s, 3 H), 2.80 (s, 2 H), 3.00 (m, 1 H), 3.12 (s, 3 H), 3.28 (s, 1 H), 3.64 (d, J=11.72 Hz, 1 H), 4.23 (dd, J=15.29, 7.96 Hz, 1 H), 4.47 (d, J=14.65 Hz, 1 H), 7.22 (m, 4 H), 7.91 (d, J=8.24 Hz, 3 H), 8.11 (d, J=8.42 Hz, 2 H), 10.02 (s, 1 H)	387





18		4-Bromo-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	1H NMR (300 MHz, DMSO-D6) δ ppm 1.43 (m, 2 H), 1.71 (m, 2 H), 2.76 (s, 2 H), 3.07 (m, 4 H), 3.28 (m, 1 H), 3.65 (d, $J=12.08$ Hz, 1 H), 4.24 (dd, $J=15.11$, 8.15 Hz, 1 H), 4.48 (d, $J=15.38$ Hz, 1 H), 7.22 (m, 3 H), 7.51 (m, 2 H), 7.76 (m, 4 H), 9.84 (s, 1 H)	423
19		Ethanesulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	1H NMR (300 MHz, DMSO-D6) δ ppm 1.17 (t, $J=7.42$ Hz, 3 H), 1.51 (m, 2 H), 1.80 (m, 2 H), 2.96 (m, 5 H), 3.17 (dd, $J=10.44$, 5.31 Hz, 3 H), 3.31 (d, $J=6.23$ Hz, 1 H), 3.68 (d, $J=10.99$ Hz, 1 H), 4.26 (dd, $J=15.66$, 7.97 Hz, 1 H), 4.50 (d, $J=13.92$ Hz, 1 H), 7.22 (m, 5 H), 10.08 (s, 1 H)	297
20		Propane-2-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	1H NMR (300 MHz, DMSO-D6) δ ppm 1.17 (s, 3 H), 1.20 (s, 3 H), 1.49 (m, 2 H), 1.80 (m, 2 H), 2.95 (m, 2 H), 3.05 (m, 1 H), 3.13 (m, 4 H), 3.32 (m, 1 H), 3.68 (d, $J=11.90$ Hz, 1 H), 4.26 (m, 1 H), 4.50 (m, 1 H), 7.04 (m, 1 H), 7.20 (m, 4 H), 9.98 (s, 1 H)	311
21		Quinoline-8-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	1H NMR (300 MHz, DMSO-D6) δ ppm 1.41 (m, 2 H), 1.68 (m, 2 H), 2.81 (s, 2 H), 3.01 (m, 1 H), 3.09 (m, 2 H), 3.16 (m, 2 H), 3.60 (d, $J=10.62$ Hz, 1 H), 4.20 (m, 1 H), 4.44 (d, $J=16.85$ Hz, 1 H), 7.20 (m, 5 H), 7.72 (m, 2 H), 8.30 (m, 2 H), 8.54 (d, $J=7.69$ Hz, 1 H), 9.07 (dd, $J=4.21$, 1.65 Hz, 1 H), 9.96 (s, 1 H)	396





22		Naphthalene-1-sulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.21 (m, 2 H), 1.34 (m, 2 H), 1.57 (d, J=7.87 Hz, 2 H), 2.78 (s, 2 H), 3.04 (m, 3 H), 3.23 (m, 2 H), 3.60 (m, 1 H), 4.19 (dd, J=15.29, 8.15 Hz, 1 H), 4.44 (d, J=14.46 Hz, 1 H), 7.18 (m, 5 H), 7.63 (m, 4 H), 7.92 (s, 1 H), 8.02 (m, 1 H), 8.13 (dd, J=16.57, 7.78 Hz, 3 H), 8.65 (d, J=8.42 Hz, 1 H), 9.87 (s, 1 H)	409
23		Naphthalene-2-sulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide	¹H NMR (300 MHz, CHLOROFORM-D) δ ppm 1.34 (m, 2 H), 1.52 (qt, J=7.23 Hz, 4 H), 1.63 (s, 1 H), 2.41 (m, 2 H), 2.66 (t, J=5.95 Hz, 2 H), 2.88 (t, J=5.86 Hz, 2 H), 2.99 (t, J=6.23 Hz, 2 H), 3.55 (s, 2 H), 4.82 (s, 1 H), 6.99 (m, 1 H), 7.10 (m, 3 H), 7.62 (m, 2 H), 7.75 (dd, J=8.61, 1.83 Hz, 1 H), 7.93 (m, 3 H), 8.40 (d, J=1.28 Hz, 1 H)	409
24		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.25 (m, 2 H), 1.39 (d, J=7.14 Hz, 2 H), 1.68 (d, J=7.69 Hz, 2 H), 2.73 (s, 2 H), 2.96 (s, 1 H), 3.14 (m, 3 H), 3.27 (d, J=10.25 Hz, 1 H), 3.66 (d, J=11.35 Hz, 1 H), 4.23 (dd, J=15.47, 7.96 Hz, 1 H), 4.49 (d, J=13.92 Hz, 1 H), 7.20 (m, 4 H), 7.58 (m, 4 H), 7.77 (m, 2 H), 10.04 (s, 1 H)	359
25		3-(4-Bromo-phenoxy)-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide	¹H NMR (300 MHz, CHLOROFORM-D) δ ppm 1.38 (m, 2 H), 1.54 (m, 4 H), 1.67 (s, 1 H), 2.47 (m, 2 H), 2.71 (t, J=5.86 Hz, 2 H), 2.93 (m, 3 H), 3.59 (s, 2 H), 4.74 (t, J=5.68 Hz, 1 H), 6.94 (m, 2 H), 7.00 (m, 3 H), 7.11 (m, 3 H), 7.51 (m, 2 H), 7.75 (m, 2 H)	529





26		Thiophene-2-sulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.31 (d, J=6.96 Hz, 2 H), 1.44 (m, 2 H), 1.69 (s, 2 H), 2.82 (s, 2 H), 3.14 (m, 5 H), 3.67 (d, J=9.70 Hz, 1 H), 4.24 (m, 1 H), 4.50 (d, J=17.21 Hz, 1 H), 7.18 (m, 5 H), 7.55 (m, 1 H), 7.83 (m, 2 H), 10.05 (s, 1 H)	365
27		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-2-nitrobenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.30 (d, J=6.96 Hz, 2 H), 1.47 (d, J=6.77 Hz, 2 H), 1.68 (m, 2 H), 2.89 (d, J=5.49 Hz, 3 H), 3.11 (m, 3 H), 3.26 (d, J=7.32 Hz, 1 H), 3.65 (d, J=10.62 Hz, 1 H), 4.22 (m, 1 H), 4.48 (m, 1 H), 7.18 (m, 4 H), 7.81 (m, 3 H), 7.97 (ddd, J=5.22, 3.94, 1.46 Hz, 2 H), 9.99 (s, 1 H)	404
28		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-3-nitrobenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.28 m, 2 H), 1.41 (d, J=7.32 Hz, 2 H), 1.68 (m, 2 H), 2.79 (s, 2 H), 3.08 (m, 4 H), 3.26 (m, 1 H), 3.67 (m, 1 H), 4.23 (m, 1 H), 4.49 (d, J=15.38 Hz, 1 H), 7.19 (m, 4 H), 7.85 (t, J=7.96 Hz, 1 H), 7.98 (s, 1 H), 8.18 (m, 1 H), 8.43 (dt, J=8.29, 1.17 Hz, 1 H), 8.52 (t, J=1.92 Hz, 1 H), 10.04 (s, 1 H)	404
29		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-4-fluorobenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.28 (m, 2 H), 1.40 (m, 2 H), 1.67 (m, 2 H), 2.72 (m, 2 H), 3.02 (m, 1 H), 3.11 (m, 3 H), 3.27 (m, J=8.24 Hz, 1 H), 3.66 (m, J=11.35 Hz, 1 H), 4.24 (dd, J=15.47, 8.33 Hz, 1 H), 4.49 (d, J=14.83 Hz, 1 H), 7.21 (m, 4 H), 7.37 (d, J=6.77 Hz, 2 H), 7.64 (s, 1 H), 7.83 (m, 2 H), 9.96 (s, 1 H)	377





30		4-Bromo-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)pentyl]benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.25 (m, 2 H), 1.40 (m, 2 H), 1.68 (ddd, $J=15.38$, 7.96, 7.78 Hz, 2 H), 2.73 (m, 2 H), 2.99 (m, 1 H), 3.12 (d, $J=6.96$ Hz, 3 H), 3.27 (m, $J=9.16$ Hz, 1 H), 3.68 (m, 1 H), 4.23 (dd, $J=15.38$, 8.06 Hz, 1 H), 4.50 (m, 1 H), 7.21 (m, 4 H), 7.72 (m, 5 H), 10.04 (s, 1 H)	437
31		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)pentyl]-4-methylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.28 (d, $J=6.41$ Hz, 2 H), 1.41 (d, $J=6.96$ Hz, 2 H), 1.68 (m, 2 H), 2.33 (s, 3 H), 2.70 (t, $J=6.23$ Hz, 2 H), 2.98 (m, 1 H), 3.13 (d, $J=5.68$ Hz, 3 H), 3.26 (m, $J=8.97$ Hz, 1 H), 3.65 (d, $J=10.80$ Hz, 1 H), 4.22 (m, 1 H), 4.48 (d, $J=15.38$ Hz, 1 H), 7.20 (m, 4 H), 7.34 (d, $J=8.06$ Hz, 2 H), 7.50 (s, 1 H), 7.65 (d, $J=7.87$ Hz, 2 H), 10.11 (s, 1 H)	373
32		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)pentyl]-2,4-dimethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.25 (m, 2 H), 1.40 (m, 2 H), 1.64 (m, 2 H), 2.27 (s, 3 H), 2.49 (s, 3 H), 2.72 (m, 2 H), 3.01 (m, 1 H), 3.11 (m, 3 H), 3.26 (m, $J=8.06$ Hz, 1 H), 3.65 (d, $J=11.35$ Hz, 1 H), 4.23 (dd, $J=15.66$, 8.33 Hz, 1 H), 4.48 (d, $J=15.56$ Hz, 1 H), 7.16 (m, 6 H), 7.51 (s, 1 H), 7.65 (d, $J=7.87$ Hz, 1 H), 9.83 (s, 1 H)	387
33		2-Naphthalen-1-yl-ethanesulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)pentyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.36 (m, 2 H), 1.51 (m, 2 H), 1.76 (m, 2 H), 3.00 (m, 3 H), 3.15 (m, 3 H), 3.33 (m, 3 H), 3.43 (m, 2 H), 3.69 (m, 1 H), 4.25 (dd, $J=15.38$, 8.24 Hz, 1 H), 4.50 (d, $J=14.65$ Hz, 1 H), 7.21 (m, 5 H), 7.42 (m, 2 H), 7.55 (m, 2 H), 7.79 (m, 1 H), 7.91 (d, $J=8.24$ Hz, 1 H), 8.00 (d, $J=8.42$ Hz, 1 H), 10.11 (s, 1 H)	437





34		Quinoline-8-sulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.20 (m, 2 H), 1.36 (m, 2 H), 1.59 (m, 2 H), 2.78 (t, J=6.50 Hz, 2 H), 3.04 (m, 4 H), 3.23 (m, 1 H), 3.61 (m, 1 H), 4.20 (dd, J=15.47, 8.15 Hz, 1 H), 4.45 (d, J=15.20 Hz, 1 H), 7.18 (m, 5 H), 7.69 (m, 2 H), 8.27 (dd, J=15.29, 7.60 Hz, 2 H), 8.52 (m, 1 H), 9.05 (dd, J=4.12, 1.56 Hz, 1 H), 9.80 (s, 1 H)	410
35		5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.27 (m, 2 H), 1.42 (m, 2 H), 1.65 (m, 2 H), 2.62 (s, 3 H), 2.89 (m, 2 H), 3.06 (m, 4 H), 3.25 (m, 1 H), 3.62 (d, J=10.25 Hz, 1 H), 4.20 (dd, J=15.56, 8.06 Hz, 1 H), 4.45 (d, J=15.20 Hz, 1 H), 7.19 (m, 4 H), 7.51 (dt, J=8.70, 1.88 Hz, 1 H), 8.00 (m, 2 H), 8.14 (s, 1 H), 9.88 (s, 1 H)	463
36		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.42 (m, 2 H), 1.66 (m, 2 H), 2.04 (m, 6 H), 2.56 (s, 3 H), 2.73 (t, J=6.41 Hz, 2 H), 3.01 (m, 1 H), 3.09 (m, 3 H), 3.23 (m, 1 H), 3.61 (d, J=11.17 Hz, 1 H), 3.76 (s, 3 H), 4.20 (dd, J=15.47, 7.96 Hz, 1 H), 4.44 (d, J=14.65 Hz, 1 H), 6.76 (s, 1 H), 7.20 (m, 4 H), 7.37 (s, 1 H), 10.16 (s, 1 H)	417
37		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.25 (m, J=6.59 Hz, 2 H), 1.38 (m, 2 H), 1.63 (m, J=7.32 Hz, 2 H), 2.06 (m, 6 H), 2.56 (s, 3 H), 2.70 (m, 2 H), 3.05 (m, 4 H), 3.25 (m, 1 H), 3.64 (d, J=11.35 Hz, 1 H), 3.75 (s, 3 H), 4.22 (dd, J=15.11, 8.15 Hz, 1 H), 4.47 (d, J=14.65 Hz, 1 H), 6.76 (s, 1 H), 7.21 (m, 5 H), 10.03 (s, 1 H)	431





38		2-Bromo-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.45 (m, 2 H), 1.72 (m, 2 H), 2.87 (q, J=6.04 Hz, 2 H), 2.99 (m, 1 H), 3.12 (m, 3 H), 3.26 (m, 1 H), 3.64 (d, J=12.08 Hz, 1 H), 4.23 (dd, J=15.29, 7.96 Hz, 1 H), 4.46 (m, 1 H), 7.20 (m, 4 H), 7.50 (m, 2 H), 7.81 (d, J=7.32 Hz, 1 H), 7.90 (s, 1 H), 7.97 (d, J=7.51 Hz, 1 H), 9.93 (s, 1 H)	423
39		2-Bromo-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)pentyl]benzenesulfonamide hydrochloride		437
40		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)butyl]-4-(trifluoromethoxy)benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.45 (m, 2 H), 1.73 (m, 2 H), 2.78 (s, 2 H), 2.99 (m, 1 H), 3.14 (m, 3 H), 3.26 (d, J=6.96 Hz, 1 H), 3.65 (m, 1 H), 4.24 (m, 1 H), 4.48 (d, J=15.20 Hz, 1 H), 7.19 (m, 4 H), 7.53 (d, J=8.61 Hz, 2 H), 7.90 (m, 3 H), 10.12 (s, 1 H)	429
41		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)butyl]-2-nitro-4-(trifluoromethyl)benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.50 (m, 2 H), 1.75 (m, 2 H), 2.97 (m, 3 H), 3.14 (m, 3 H), 3.31 (m, 1 H), 3.65 (m, 1 H), 4.24 (dd, J=15.38, 8.30 Hz, 1 H), 4.48 (d, J=14.65 Hz, 1 H), 7.20 (m, 4 H), 8.20 (m, 2 H), 8.47 (s, 2 H), 10.01 (s, 1 H)	458





42		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-3-fluorobenzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.72 (m, 2 H), 2.78 (s, 2 H), 2.99 (m, 1 H), 3.12 (m, 3 H), 3.27 (m, 1 H), 3.65 (m, 1 H), 4.23 (dd, J=14.92, 8.33 Hz, 1 H), 4.47 (d, J=16.11 Hz, 1 H), 7.18 (m, 4 H), 7.41 (m, J=7.64, 5.36, 1 H), 7.58 (m, 3 H), 7.79 (s, 1 H), 9.91 (s, 1 H)	363
43		2,4-Dichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]benzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.70 (m, 2 H), 2.86 (q, J=6.51 Hz, 2 H), 2.95 (m, 1 H), 3.12 (m, 3 H), 3.26 (m, 1 H), 3.63 (d, J=11.23 Hz, 1 H), 4.22 (dd, J=15.38, 7.57 Hz, 1 H), 4.45 (m, 1 H), 7.20 (m, 4 H), 7.55 (m, 1 H), 7.75 (m, 1 H), 7.93 (m, 1 H), 8.03 (s, 1 H), 10.06 (s, 1 H)	413
44		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2,4,6-trimethylbenzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.41 (m, 2 H), 1.68 (m, 2 H), 2.18 (s, 3 H), 2.53 (s, 6 H), 2.74 (m, 2 H), 3.06 (m, 4 H), 3.25 (m, 1 H), 3.63 (m, 1 H), 4.21 (dd, J=15.56, 7.51 Hz, 1 H), 4.45 (d, J=14.28 Hz, 1 H), 6.98 (s, 2 H), 7.20 (m, 4 H), 7.45 (s, 1 H), 9.96 (s, 1 H)	387
45		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2-trifluoromethylbenzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.50 (m, 2 H), 1.74 (d, J=6.59 Hz, 2 H), 2.91 (m, 2 H), 3.02 (m, 1 H), 3.14 (m, J=6.59 Hz, 3 H), 3.27 (m, 1 H), 3.64 (m, 1 H), 4.24 (dd, J=15.38, 8.42 Hz, 1 H), 4.47 (d, J=15.20 Hz, 1 H), 7.20 (m, 4 H), 7.79 (m, 2 H), 7.90 (d, J=7.51 Hz, 1 H), 8.06 (d, J=7.51 Hz, 2 H), 9.92 (s, 1 H)	413




46		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-4-trifluoromethoxybenzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.26 (m, 2 H), 1.40 (m, 2 H), 1.66 (m, 2 H), 2.74 (t, J=6.87 Hz, 2 H), 2.97 (m, 1 H), 3.11 (m, 3 H), 3.26 (m, 1 H), 3.64 (m, 1 H), 4.22 (dd, J=15.38, 8.24 Hz, 1 H), 4.47 (m, 1 H), 7.18 (m, 4 H), 7.45 (d, J=8.61 Hz, 2 H), 7.68 (s, 1 H), 7.87 (m, 2 H), 9.80 (s, 1 H)	443
47		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-2-nitro-4-trifluoromethylbenzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.29 (m, 2 H), 1.47 (m, 2 H), 1.68 (m, 2 H), 2.92 (q, J=6.53 Hz, 2 H), 3.01 (m, 1 H), 3.11 (m, 3 H), 3.28 (m, 1 H), 3.66 (m, 1 H), 4.23 (dd, J=15.20, 8.42 Hz, 1 H), 4.48 (d, J=15.56 Hz, 1 H), 7.17 (m, 4 H), 8.18 (m, 2 H), 8.38 (s, 2 H), 9.74 (s, 1 H)	472
48		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-3-fluorobenzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.28 (m, 2 H), 1.40 (m, 2 H), 1.66 (m, 2 H), 2.75 (d, J=6.35 Hz, 2 H), 2.98 (m, 1 H), 3.09 (m, 3 H), 3.25 (m, 1 H), 3.66 (m, 1 H), 4.25 (d, J=8.06 Hz, 1 H), 4.47 (d, J=14.40 Hz, 1 H), 7.19 (m, 4 H), 7.36 (m, 1 H), 7.57 (m, 4 H), 9.86 (s, 1 H)	377
49		2,4-Dichloro-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]benzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D6) δ ppm 1.26 (m, 2 H), 1.40 (m, 2 H), 1.64 (m, 2 H), 2.80 (m, 2 H), 2.95 (m, 1 H), 3.09 (m, 3 H), 3.26 (m, 1 H), 3.63 (d, J=10.01 Hz, 1 H), 4.21 (dd, J=15.26, 7.93 Hz, 1 H), 4.45 (d, J=15.38 Hz, 1 H), 7.15 (m, 4 H), 7.48 (dd, J=8.55, 2.20 Hz, 1 H), 7.67 (d, J=2.20 Hz, 1 H), 7.90 (d, J=8.55 Hz, 2 H), 9.88 (s, 1 H)	427






50		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-2,4,6-trimethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.25 (m, 2 H), 1.37 (m, 2 H), 1.64 (m, 2 H), 2.19 (s, 3 H), 2.51 (s, 6 H), 2.71 (t, J=6.35 Hz, 2 H), 3.06 (m, 4 H), 3.22 (m, 1 H), 3.63 (d, J=10.74 Hz, 1 H), 4.21 (dd, J=15.26, 8.18 Hz, 1 H), 4.46 (d, J=14.89 Hz, 1 H), 6.95 (s, 2 H), 7.20 (m, 4 H), 7.36 (s, 1 H), 10.04 (s, 1 H)	401
51		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-2-trifluoromethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.30 (m, 2 H), 1.46 (m, 2 H), 1.69 (m, 2 H), 2.87 (m, 2 H), 2.97 (m, 1 H), 3.12 (m, 3 H), 3.27 (d, J=11.47 Hz, 1 H), 3.66 (d, J=10.74 Hz, 1 H), 4.23 (dd, J=15.50, 8.18 Hz, 1 H), 4.48 (d, J=14.89 Hz, 1 H), 7.19 (m, 4 H), 7.77 (m, 2 H), 7.88 (d, J=7.81 Hz, 2 H), 8.04 (d, J=7.81 Hz, 1 H), 9.94 (s, 1 H)	427
52		2,3-Dichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.46 (m, 2 H), 1.77 (m, 2 H), 2.88 (q, J=6.71 Hz, 2 H), 3.00 (s, 1 H), 3.15 (s, 4 H), 3.60 (m, 1 H), 4.20 (dd, J=15.29, 7.60 Hz, 1 H), 4.43 (m, 1 H), 7.20 (m, 4 H), 7.56 (t, J=7.96 Hz, 1 H), 7.95 (m, 2 H), 8.21 (m, 1 H), 10.98 (s, 1 H)	413
53		2,4,5-Trichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.46 (m, 2 H), 1.75 (m, 2 H), 2.87 (s, 2 H), 3.01 (m, 1 H), 3.12 (m, 3 H), 3.23 (m, 1 H), 3.61 (m, 1 H), 4.21 (dd, J=15.01, 8.06 Hz, 1 H), 4.44 (d, J=15.93 Hz, 1 H), 7.23 (m, 4 H), 8.07 (m, 1 H), 8.13 (m, 1 H), 8.28 (s, 1 H), 10.83 (s, 1 H)	447






54		5-Bromo-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]-2-methoxybenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.77 (m, 2 H), 2.81 (q, J=6.77 Hz, 2 H), 2.98 (m, 1 H), 3.10 (m, 2 H), 3.24 (m, 2 H), 3.61 (m, 1 H), 3.89 (s, 3 H), 4.20 (m, 1 H), 4.44 (m, 1 H), 7.22 (m, 5 H), 7.56 (t, J=5.95 Hz, 1 H), 7.78 (m, 2 H), 11.03 (s, 1 H)	453
55		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)butyl]-2,5-dimethoxybenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.76 (m, 2 H), 2.79 (q, J=6.65 Hz, 2 H), 2.98 (m, 1 H), 3.09 (m, 2 H), 3.22 (m, 2 H), 3.61 (m, 1 H), 3.74 (s, 3 H), 3.84 (s, 3 H), 4.21 (m, 1 H), 4.44 (d, J=15.20 Hz, 1 H), 7.22 (m, 7 H), 7.33 (t, J=5.95 Hz, 1 H), 10.89 (s, 1 H)	405
56		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)butyl]-2,3,4,5,6-pentamethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.43 (m, 2 H), 1.73 (m, 2 H), 2.18 (s, 6 H), 2.22 (s, 3 H), 2.48 (s, 6 H), 2.74 (q, J=6.59 Hz, 2 H), 2.97 (m, 1 H), 3.09 (s, 2 H), 3.19 (d, J=9.34 Hz, 2 H), 3.58 (m, 1 H), 4.18 (dd, J=15.66, 7.78 Hz, 1 H), 4.43 (m, 1 H), 7.23 (m, 4 H), 7.48 (t, J=5.86 Hz, 1 H), 10.80 (s, 1 H)	415
57		2-(2,2,2-Trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]-amide fumarate		496

58		2,3-Dichloro-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.25 (m, 2 H), 1.42 (m, 2 H), 1.71 (m, 2 H), 2.86 (q, J=6.71 Hz, 2 H), 2.95 (m, 1 H), 3.07 (m, 2 H), 3.21 (m, 2 H), 3.62 (m, 1 H), 4.19 (d, J=7.69 Hz, 1 H), 4.23 (s, 1 H), 4.47 (d, J=15.93 Hz, 4 H), 7.22 (m, 4 H), 7.56 (t, J=8.06 Hz, 1 H), 7.93 (ddd, J=7.92, 6.36, 1.46 Hz, 2 H), 8.14 (m, 1 H), 10.70 (s, 1 H)	427
59		2,4,5-Trichloro-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.27 (m, 2 H), 1.44 (m, 2 H), 1.73 (m, 2 H), 2.88 (m, J=6.04 Hz, 2 H), 2.99 (m, 1 H), 3.08 (m, 2 H), 3.23 (m, 2 H), 3.61 (m, 1 H), 4.21 (dd, J=15.20, 7.51 Hz, 1 H), 4.46 (d, J=15.01 Hz, 1 H), 7.22 (m, 4 H), 8.06 (s, 1 H), 8.13 (s, 1 H), 8.22 (m, 1 H), 10.93 (s, 1 H)	461
60		5-Bromo-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-2-methoxybenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.28 (m, 2 H), 1.41 (m, 2 H), 1.70 (m, 2 H), 2.79 (m, 2 H), 2.98 (m, 1 H), 3.08 (m, 2 H), 3.21 (m, 2 H), 3.61 (m, 1 H), 3.89 (s, 3 H), 4.22 (dd, J=14.83, 8.24 Hz, 1 H), 4.47 (d, J=16.66 Hz, 1 H), 7.19 (s, 2 H), 7.24 (dd, J=6.32, 3.39 Hz, 3 H), 7.50 (m, 1 H), 7.78 (m, 2 H), 10.63 (s, 1 H)	467
61		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-2,5-dimethoxybenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.26 (m, 2 H), 1.40 (m, 2 H), 1.69 (m, 2 H), 2.77 (q, J=6.41 Hz, 2 H), 3.08 (m, 3 H), 3.22 (m, 2 H), 3.66 (m, 1 H), 3.74 (s, 3 H), 3.83 (s, 3 H), 4.22 (dd, J=15.84, 8.88 Hz, 1 H), 4.47 (d, J=15.01 Hz, 1 H), 7.23 (m, 8 H), 10.51 (s, 1 H)	419






62		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-2,3,4,5,6-pentamethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.26 (m, 2 H), 1.41 (m, 2 H), 1.69 (m, 2 H), 2.18 (s, 6 H), 2.22 (s, 3 H), 2.47 (s, 6 H), 2.72 (q, J=6.47 Hz, 2 H), 3.03 (m, 3 H), 3.23 (m, 2 H), 3.63 (m, 1 H), 4.20 (dd, J=15.66, 7.78 Hz, 1 H), 4.46 (d, J=15.56 Hz, 1 H), 7.23 (m, 4 H), 7.41 (t, J=5.77 Hz, 1 H), 10.67 (s, 1 H)	429
63		2-(2,2,2-Trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.29 (m, 2 H), 1.41 (m, 2 H), 1.45 (s, 2 H), 1.73 (m, 2 H), 2.74 (m, 2 H), 2.99 (m, 1 H), 3.08 (m, 2 H), 3.24 (m, 2 H), 3.63 (m, 1 H), 3.81 (m, 2 H), 4.21 (m, 1 H), 4.47 (m, 1 H), 4.84 (m, 2 H), 7.24 (m, 4 H), 7.42 (d, J=8.24 Hz, 1 H), 7.63 (m, 3 H), 10.82 (s, 1 H)	510
64		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2-methyl-5-nitrobenzenesulfonamide hydrochloride		404
65		4-Bromo-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-difluorobenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.46 (m, 2 H), 1.75 (m, 2 H), 2.91 (m, 2 H), 3.02 (m, 1 H), 3.15 (m, 2 H), 3.24 (m, 2 H), 3.63 (m, 1 H), 4.23 (dd, J=14.79, 7.32 Hz, 1 H), 4.46 (d, J=14.35 Hz, 1 H), 7.25 (m, 4 H), 7.72 (dd, J=7.76, 6.15 Hz, 1 H), 8.06 (dd, J=9.15, 5.34 Hz, 1 H), 8.27 (m, 1 H), 10.44 (s, 1 H)	459






66		4-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]-2,5-dimethylbenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.42 (m, 2 H), 1.69 (m, 2 H), 2.28 (s, 3 H), 2.48 (s, 3 H), 2.77 (t, J=5.37 Hz, 2 H), 2.97 (m, 1 H), 3.10 (d, J=6.35 Hz, 3 H), 3.25 (d, J=9.03 Hz, 1 H), 3.61 (m, 1 H), 4.21 (dd, J=15.63, 8.30 Hz, 1 H), 4.44 (m, 1 H), 7.16 (m, 4 H), 7.36 (s, 1 H), 7.71 (s, 2 H), 9.91 (s, 1 H)	407
67		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)butyl]-3-methoxybenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.43 (m, 2 H), 1.72 (m, 2 H), 2.76 (t, J=6.59 Hz, 2 H), 2.98 (m, 1 H), 3.12 (m, 3 H), 3.26 (m, 1 H), 3.63 (m, 1 H), 3.77 (s, 3 H), 4.22 (dd, J=15.14, 8.06 Hz, 1 H), 4.46 (m, 1 H), 7.18 (m, 5 H), 7.31 (m, 2 H), 7.43 (t, J=7.93 Hz, 1 H), 7.62 (s, 1 H), 9.95 (s, 1 H)	375
68		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)butyl]-4-isopropylbenzenesulfonamide hydrochloride		387
69		3-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]-4-fluorobenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.72 (m, 2 H), 2.78 (t, J=6.84 Hz, 2 H), 2.99 (m, 1 H), 3.11 (m, 3 H), 3.27 (m, 1 H), 3.65 (m, 1 H), 4.23 (m, 1 H), 4.47 (m, 1 H), 7.19 (m, 4 H), 7.56 (t, J=8.91 Hz, 1 H), 7.78 (ddd, J=8.67, 4.52, 2.20 Hz, 2 H), 7.93 (dd, J=6.84, 2.44 Hz, 1 H), 9.82 (s, 1 H)	397

70		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-3-methyl-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.72 (m, 2 H), 2.37 (s, 3 H), 2.75 (m, 2 H), 3.00 (m, 1 H), 3.12 (m, 3 H), 3.27 (m, 1 H), 3.64 (m, 1 H), 4.24 (dd, $J=14.77$, 8.42 Hz, 1 H), 4.48 (d, $J=14.40$ Hz, 1 H), 7.24 (d, $J=6.10$ Hz, 4 H), 7.43 (s, 2 H), 7.59 (s, 3 H), 9.90 (s, 1 H)	359
71		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-5-fluoro-2-methyl-benzenesulfonamide hydrochloride		377
72		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-4-isopropoxy-benzenesulfonamide hydrochloride		403
73		3-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride		379
74		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-3,4-dimethoxy-benzenesulfonamide hydrochloride		405






75		N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,3,4,5,6-pentafluorobenzenesulfonamide hydrochloride	435
76		2-Oxo-2H-chromene-6-sulfonic acid [5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	487
77		2-Oxo-2H-chromene-6-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	413
78		3,5-Dichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	413
79		2,5-Dichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	413






¹H NMR (300 MHz, DMSO-D6) δ ppm 1.45 (m, 2 H), 1.75 (m, 2 H), 2.89 (q, J=6.74 Hz, 2 H), 2.96 (m, 1 H), 3.10 (m, 3 H), 3.21 (m, 1 H), 3.63 (m, 1 H), 4.21 (dd, J=15.23, 8.05 Hz, 1 H), 4.44 (d, J=14.94 Hz, 1 H), 7.22 (m, 4 H), 7.73 (m, 2 H), 7.91 (d, J=2.34 Hz, 1 H), 8.19 (t, J=5.71 Hz, 1 H), 10.62 (s, 1 H)

80		5-Bromo-6-chloro-pyridine-3-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	458
81		4-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-benzenesulfonamide butyl]-benzenesulfonamide hydrochloride	379
82		2,6-Dichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	413
83		1-Methyl-1H-imidazole-4-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	349
84		5-Bromo-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,4-difluoro-benzenesulfonamide hydrochloride	459





85		6-Chloro-imidazo[2,1-b]thiazole-5-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	425
86		2-Oxo-2H-chromene-6-sulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	427
87		3,5-Dichloro-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	427
88		2,5-Dichloro-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	427
89		5-Bromo-6-chloro-pyridine-3-sulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide	473






¹H NMR (300 MHz, DMSO-D6) δ ppm 1.28 (m, 2 H), 1.42 (m, 2 H), 1.70 (m, 2 H), 2.88 (m, 2 H), 2.98 (m, 1 H), 3.08 (m, 3 H), 3.20 (m, 1 H), 3.66 (m, 1 H), 4.22 (dd, J=15.45, 5.78 Hz, 1 H), 4.47 (m, 1 H), 7.21 (m, 4 H), 7.71 (m, 2 H), 7.91 (s, 1 H), 8.12 (t, J=5.42 Hz, 1 H), 10.59 (s, 1 H)






90		4-Chloro-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	393
91		3,5-Dichloro-N-[5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide	487
92		2,5-Dichloro-N-[5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	487
93		5-Bromo-6-chloro-pyridine-3-sulfonic acid [5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	532
94		4-Chloro-N-[5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	453





95		2-Oxo-2H-chromene-6-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	473
96		3,5-Dichloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	473
97		2,5-Dichloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	473
98		5-Bromo-6-chloro-pyridine-3-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	518
99		4-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	439





¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.46 (m, 2 H), 1.74 (m, 2 H), 2.89 (m, 3 H), 3.06 (m, 3 H), 3.23 (m, 1 H), 3.57 (m, 1 H), 3.70 (s, 3 H), 3.72 (s, 3 H), 4.09 (m, 1 H), 4.33 (d, J=14.94 Hz, 1 H), 6.77 (d, J=11.27 Hz, 2 H), 7.73 (m, 2 H), 7.91 (d, J=2.20 Hz, 1 H), 8.18 (t, J=5.71 Hz, 1 H), 10.49 (s, 1 H)





100		2-Oxo-2H-chromene-6-sulfonic acid [6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-amide hydrochloride	441
101		3,5-Dichloro-N-[6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-benzenesulfonamide hydrochloride	441
102		2,5-Dichloro-N-[6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-benzenesulfonamide hydrochloride	441
103		5-Bromo-6-chloro-pyridine-3-sulfonic acid [6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-amide hydrochloride	486






104		2,6-Dichloro-N-[6-(3,4-dihydro-1H-isoquinolin-2-yl)hexyl]benzenesulfonamide hydrochloride		441
105		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)pentyl]-2-methyl-5-nitrobenzenesulfonamide hydrochloride		418
106		4-Bromo-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)pentyl]-2,5-difluorobenzenesulfonamide hydrochloride		473
107		4-Chloro-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)pentyl]-2,5-dimethylbenzenesulfonamide hydrochloride		421
108		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)pentyl]-4-isopropylbenzenesulfonamide hydrochloride		401






109		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-3-methylbenzenesulfonamide hydrochloride		373
110		3-Chloro-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-4-fluorobenzenesulfonamide hydrochloride		411
111		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-5-fluoro-2-methylbenzenesulfonamide hydrochloride		391
112		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-3-methoxybenzenesulfonamide hydrochloride		389
113		3-Chloro-N-[5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]benzenesulfonamide hydrochloride		393






114		N-[5-(3,4-Dihydro-1H-isoquinolin-2-yl)-pentyl]-3,4-dimethoxybenzenesulfonamide hydrochloride	419
115		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-difluorobenzenesulfonamide hydrochloride	441
116		5-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,4-difluorobenzenesulfonamide	475
117		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,3,4-trifluorobenzenesulfonamide hydrochloride	459

118		2-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.70 (m, 2 H), 2.86 (m, 3 H), 3.07 (m, 2 H), 3.18 (m, 2 H), 3.56 (m, 1 H), 3.70 (s, 3 H), 3.71 (s, 3 H), 4.10 (dd, J=14.86, 7.25 Hz, 1 H), 4.33 (m, 1 H), 6.77 (d, J=11.57 Hz, 2 H), 7.53 (m, 1 H), 7.65 (ddd, J=14.86, 7.98, 1.76 Hz, 2 H), 7.97 (m, 2 H), 10.40 (s, 1 H)	439
119		N-[5-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-2,5-difluorobenzenesulfonamide hydrochloride		455
120		5-Chloro-N-[5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide		489
121		N-[5-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-2,3,4-trifluorobenzenesulfonamide hydrochloride		473





122		2-Chloro-N-[5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	453
123		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,6-difluorobenzenesulfonamide hydrochloride	441
124		2-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4,5-difluorobenzenesulfonamide	475
125		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,4,5-trifluorobenzenesulfonamide	459






126		3-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.74 (m, 2 H), 2.78 (q, J=6.59 Hz, 2 H), 2.89 (m, 1 H), 3.09 (m, 3 H), 3.19 (m, 1 H), 3.59 (m, 1 H), 3.70 (s, 3 H), 3.72 (s, 3 H), 4.09 (m, 1 H), 4.35 (m, 1 H), 6.78 (d, J=9.52 Hz, 2 H), 7.64 (m, 1 H), 7.75 (m, 3 H), 7.90 (t, J=5.78 Hz, 1 H), 10.47 (s, 1 H)	439
127		N-[5-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-2,6-difluorobenzenesulfonamide hydrochloride		455
128		2-Chloro-N-[5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-4,5-difluorobenzenesulfonamide		489
129		N-[5-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-2,4,5-trifluorobenzenesulfonamide		473
130		3-Chloro-N-[5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride		453






131		Biphenyl-4-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	481
132		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-methyl-5-nitro-benzenesulfonamide hydrochloride	464
133		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-C-phenyl-methanesulfonamide hydrochloride	419
134		Biphenyl-4-sulfonic acid [5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide	495
135		N-[5-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-C-phenyl-methanesulfonamide hydrochloride	433

136		Benzo[b]thiophene-3-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	401
137		7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide	421
138		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2,4-dinitro-benzenesulfonamide hydrochloride	435
139		Benzo[b]thiophene-2-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	401
140		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-difluoro-benzenesulfonamide hydrochloride	381




¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.46 (m, 2 H), 1.75 (m, 2 H), 2.90 (m, 2 H), 3.01 (m, 1 H), 3.13 (m, 3 H), 3.24 (m, 1 H), 3.64 (m, 1 H), 4.21 (m, 1 H), 4.45 (m, 1 H), 7.23 (m, 4 H), 7.56 (m, 3 H), 8.19 (t, J=5.64 Hz, 1 H), 10.59 (s, 1 H)






141		4-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]-2,5-difluorobenzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.47 (m, 2 H), 1.75 (m, 2 H), 2.91 (q, J=6.69 Hz, 2 H), 3.01 (m, 1 H), 3.12 (m, 2 H), 3.23 (m, 2 H), 3.64 (m, 1 H), 4.21 (dd, J=14.64, 7.32 Hz, 1 H), 4.45 (d, J=15.67 Hz, 1 H), 7.22 (m, 4 H), 7.77 (dd, J=8.27, 6.22 Hz, 1 H), 7.97 (dd, J=9.44, 5.78 Hz, 1 H), 8.28 (t, J=5.78 Hz, 1 H), 10.59 (s, 1 H)	415
142		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)butyl]-2,4,5-trifluorobenzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.45 (m, 2 H), 1.74 (m, 2 H), 2.92 (m, 3 H), 3.15 (m, 2 H), 3.24 (m, 2 H), 3.63 (m, 1 H), 4.21 (dd, J=15.23, 7.47 Hz, 1 H), 4.45 (m, 1 H), 7.22 (m, 4 H), 7.86 (m, 2 H), 8.22 (m, 1 H), 10.65 (s, 1 H)	399
143		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)butyl]-2,6-difluorobenzenesulfonamide hydrochloride		381
144		5-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]-2,4-difluorobenzenesulfonamide hydrochloride	¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.46 (m, 2 H), 1.76 (m, 2 H), 2.89 (q, J=6.74 Hz, 2 H), 3.01 (m, 1 H), 3.18 (m, 4 H), 3.61 (m, 1 H), 4.21 (dd, J=15.23, 7.47 Hz, 1 H), 4.45 (m, 1 H), 7.16 (s, 1 H), 7.24 (m, 3 H), 7.85 (t, J=9.66 Hz, 1 H), 7.93 (t, J=7.69 Hz, 1 H), 8.24 (t, J=5.64 Hz, 1 H), 10.60 (s, 1 H)	415





145		2-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.73 (m, 2 H), 2.85 (q, J=6.74 Hz, 2 H), 3.01 (m, 1 H), 3.09 (m, 2 H), 3.23 (m, 2 H), 3.59 (m, 1 H), 4.20 (m, 1 H), 4.43 (m, 1 H), 7.22 (m, 4 H), 7.53 (m, 1 H), 7.63 (m, 2 H), 7.96 (m, 2 H), 10.57 (s, 1 H)	379
146		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-3,4-difluorobenzenesulfonamide		381
147		2-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4,5-difluorobenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D6) δ ppm 1.44 (m, 2 H), 1.74 (m, 2 H), 2.87 (m, 2 H), 2.98 (m, 1 H), 3.11 (s, 3 H), 3.21 (s, 1 H), 3.60 (m, 1 H), 4.21 (dd, J=14.28, 6.81 Hz, 1 H), 4.44 (m, 1 H), 7.22 (m, 4 H), 7.98 (m, 2 H), 8.19 (t, J=5.34 Hz, 1 H), 10.58 (s, 1 H)	415
148		Benzo[1,2,5]oxadiazole-4-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride		387
149		3,4-Dichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride		413




150		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-3,4-difluorobenzenesulfonamide hydrochloride	441
151		2-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4,5-difluorobenzenesulfonamide hydrochloride	475
152		Benzo[1,2,5]oxadiazole-4-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide	447
153		Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	463
154		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,4-difluorobenzenesulfonamide hydrochloride	441







¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.44 (m, 2 H), 1.72 (m, 2 H), 2.86 (d, J=6.44 Hz, 2 H), 2.89 (m, 1 H), 3.10 (m, 4 H), 3.57 (m, 1 H), 3.69 (s, 3 H), 3.70 (s, 3 H), 4.09 (dd, J=15.08, 7.17 Hz, 1 H), 4.32 (d, J=14.20 Hz, 1 H), 6.76 (d, J=10.25 Hz, 2 H), 7.28 (t, J=8.35 Hz, 1 H), 7.53 (m, 1 H), 7.83 (m, 1 H), 8.05 (t, J=5.42 Hz, 1 H), 10.47 (s, 1 H)






155		3,4-Dichloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D ₆) δ ppm 1.44 (m, 2 H), 1.73 (m, 2 H), 2.77 (m, 2 H), 2.88 (m, 1 H), 3.09 (m, 4 H), 3.58 (m, 1 H), 3.69 (s, 3 H), 3.70 (s, 3 H), 4.09 (m, 1 H), 4.34 (m, 1 H), 6.76 (d, J=9.96 Hz, 2 H), 7.74 (d, J=8.20 Hz, 1 H), 7.88 (d, J=7.91 Hz, 1 H), 7.97 (s, 2 H), 10.47 (s, 1 H)	473
156		2,3,4-Trichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D ₆) δ ppm 1.46 (m, 2 H), 1.75 (m, 2 H), 2.87 (m, 2 H), 3.00 (m, 1 H), 3.14 (d, J=5.27 Hz, 2 H), 3.24 (m, 2 H), 3.66 (d, J=2.34 Hz, 1 H), 4.23 (dd, J=15.52, 7.76 Hz, 1 H), 4.46 (d, J=15.08 Hz, 1 H), 7.23 (m, 4 H), 7.87 (m, 1 H), 7.96 (m, 1 H), 8.28 (t, J=5.56 Hz, 1 H), 10.44 (s, 1 H)	447
157		2-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-6-methyl-benzenesulfonamide hydrochloride		393
158		Thiophene-3-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	¹ H NMR (300 MHz, DMSO-D ₆) δ ppm 1.47 (m, 2 H), 1.76 (m, 2 H), 2.81 (q, J=6.39 Hz, 2 H), 3.03 (m, 1 H), 3.12 (m, 2 H), 3.26 (m, 2 H), 3.66 (m, 1 H), 4.21 (m, 1 H), 4.46 (m, 1 H), 7.25 (ddd, J=6.26, 3.51, 3.26 Hz, 4 H), 7.20 (m, 1 H), 7.25 (m, 3 H), 7.33 (m, 1 H), 7.66 (m, 1 H), 7.76 (dd, J=5.12, 2.93 Hz, 1 H), 8.15 (dd, J=2.93, 1.32 Hz, 1 H), 10.49 (s, 1 H)	351






159		2,4,6-Trichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D ₆) δ ppm 1.49 (m, 2 H), 1.77 (m, 2 H), 2.93 (q, J=6.64 Hz, 2 H), 3.01 (m, 1 H), 3.12 (m, 2 H), 3.26 (m, 2 H), 3.64 (m, 1 H), 4.21 (m, 1 H), 4.45 (m, 1 H), 7.23 (m, 4 H), 7.88 (s, 2 H), 8.33 (t, J=5.71 Hz, 1 H), 10.60 (s, 1 H)	447
160		2-Bromo-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]-4,6-difluorobenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D ₆) δ ppm 1.49 (m, 2 H), 1.76 (m, 2 H), 2.94 (q, J=6.39 Hz, 2 H), 3.04 (m, 1 H), 3.15 (m, 2 H), 3.29 (m, 2 H), 3.65 (m, 1 H), 4.25 (m, 1 H), 4.47 (m, 1 H), 7.22 (m, 4 H), 7.62 (ddd, J=11.57, 8.93, 2.64 Hz, 1 H), 7.76 (m, 1 H), 8.29 (t, J=5.86 Hz, 1 H), 10.28 (s, 1 H)	459
161		4-Bromo-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]-2-trifluoromethoxybenzenesulfonamide hydrochloride		507
162		2,3,4-Trichloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)butyl]benzenesulfonamide		507
163		2-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)butyl]-6-methylbenzenesulfonamide		453






164		Thiophene-3-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	411
165		2,4,6-Trichloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-benzenesulfonamide] hydrochloride	507
166		2-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4,6-difluorobenzenesulfonamide hydrochloride	519
167		4-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-trifluoromethoxybenzenesulfonamide] hydrochloride	567
168		2,3,4-Trichloro-N-[5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]benzenesulfonamide hydrochloride	506





169		2-Chloro-6-methyl-N-[5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	452
170		Thiophene-3-sulfonic acid [5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	410
171		2,4,6-Trichloro-N-[5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	506
172		2-Bromo-4,6-difluoro-N-[5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride	518
173		4-Bromo-N-[5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-2-trifluoromethoxy]benzenesulfonamide hydrochloride	566





174		3,4-Difluoro-N-[5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride		440
175		2-Chloro-4,5-difluoro-N-[5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride		474
176		Benzo[1,2,5]oxadiazole-4-sulfonic acid [5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride		446
177		Benzo[1,2,5]thiadiazole-4-sulfonic acid [5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride		462
178		2,4-Difluoro-N-[5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride		440
179		3,4-Dichloro-N-[5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-benzenesulfonamide hydrochloride		472





180		2,3,4-Trichloro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	494
181		2-Chloro-6-methyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	438
182		Thiophene-3-sulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide	396
183		2,4,6-Trichloro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	492
184		2-Bromo-4,6-difluoro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	504
185		4-Bromo-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-trifluoromethoxybenzenesulfonamide	552





186		3,4-Difluoro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	426
187		2-Chloro-4,5-difluoro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	460
188		Benzo[1,2,5]oxadiazole-4-sulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide	432
189		Benzo[1,2,5]thiadiazole-4-sulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide	448
190		2,4-Difluoro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	426
191		3,4-Dichloro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	458





192		4-Methyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide		404
193		2-Naphthalen-1-yl-ethanesulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide		468
194		Quinoline-8-sulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide		441
195		3-Nitro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide		435
196		2-Methyl-5-nitro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide		449





197		4-Bromo-2,5-difluoro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	504
198		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-methylbenzenesulfonamide	419
199		2-Naphthalen-1-yl-ethanesulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide	483
200		Quinoline-8-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide	456

201		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-3-nitrobenzenesulfonamide	450
202		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-5-nitrobenzenesulfonamide	464
203		4-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-difluorobenzenesulfonamide	519
204		3-Methyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]benzenesulfonamide hydrochloride	404





205		5-Fluoro-2-methyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride		422
206		4-Isopropoxy-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride		448
207		3-Chloro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride		424
208		3,4-Dimethoxy-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride		450





209		2,3,4,5,6-Pentafluoro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-1-yl)butyl]benzenesulfonamide hydrochloride	480
210		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-3-methylbenzenesulfonamide hydrochloride	419
211		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-5-fluoro-2-methylbenzenesulfonamide hydrochloride	437
212		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-isopropoxybenzenesulfonamide hydrochloride	463





213		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-3,4-dimethoxybenzenesulfonamide hydrochloride	465
214		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,3,4,5,6-pentafluorobenzenesulfonamide hydrochloride	495
215		4-Chloro-2,5-dimethyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]benzenesulfonamide hydrochloride	452
216		3-Methoxy-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]benzenesulfonamide hydrochloride	420





217		4-Isopropyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	432
218		3-Chloro-4-fluoro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	442
219		2,3,4,5,6-Pentamethyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	460
220		4-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-dimethylbenzenesulfonamide hydrochloride	467

¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.43 (m, 2 H), 1.71 (m, 2 H), 2.34 (s, 3 H), 2.77 (q, J=6.78 Hz, 2 H), 2.91 (m, 1 H), 3.09 (m, 3 H), 3.24 (m, 1 H), 3.55 (m, 1 H), 3.70 (s, 3 H), 3.72 (s, 3 H), 4.09 (m, 1 H), 4.33 (m, 1 H), 6.75 (s, 1 H), 6.79 (s, 1 H), 7.50 (s, 1 H), 7.75 (s, 1 H), 7.81 (t, J=5.78 Hz, 1 H), 10.51 (s, 1 H)





221		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-3-methoxybenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D ₆) δ ppm 1.44 (m, 2 H), 1.75 (m, 2 H), 2.76 (q, J=6.59 Hz, 2 H), 2.90 (m, 1 H), 3.09 (m, 2 H), 3.18 (m, 2 H), 3.61 (m, 1 H), 3.71 (s, 3 H), 3.72 (s, 3 H), 3.82 (s, 3 H), 4.08 (m, 1 H), 4.34 (d, J=14.64 Hz, 1 H), 6.76 (s, 1 H), 6.80 (s, 1 H), 7.21 (d, J=8.20 Hz, 1 H), 7.29 (m, 1 H), 7.35 (d, J=7.91 Hz, 1 H), 7.52 (t, J=7.91 Hz, 1 H), 7.71 (s, 1 H), 10.25 (s, 1 H)	435
222		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-isopropylbenzenesulfonamide hydrochloride		447
223		3-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-fluorobenzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D ₆) δ ppm 1.44 (m, 2 H), 1.75 (m, 2 H), 2.79 (q, J=6.59 Hz, 2 H), 2.89 (m, 1 H), 3.09 (m, 3 H), 3.23 (m, 1 H), 3.58 (m, 1 H), 3.70 (s, 3 H), 3.72 (s, 3 H), 4.09 (m, 1 H), 4.34 (d, J=14.20 Hz, 1 H), 6.76 (s, 1 H), 6.79 (s, 1 H), 7.67 (t, J=8.93 Hz, 1 H), 7.82 (m, 1 H), 7.92 (s, 1 H), 7.98 (dd, J=6.88, 2.20 Hz, 1 H), 10.51 (s, 1 H)	457
224		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,3,4,5,6-pentamethylbenzenesulfonamide		475





225		5-Dimethylamino-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide dihydrochloride	498
226		2-(2,2,2-Trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	541
227		4-Acetyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	432
228		4-Methanesulfonyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	468





229		Biphenyl-4-sulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	466
230		N-[4-(7-Nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-C-phenyl-methanesulfonamide hydrochloride	404
231		2,5-Dimethoxy-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	450
232		2-(2,2,2-Trifluoroacetyl)-1,2,3,4-tetrahydro-isoquinoline-6-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	556






233		4-Acetyl-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	447
234		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-methanesulfonylbenzenesulfonamide hydrochloride	483
235		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-dimethoxybenzenesulfonamide hydrochloride	465
236		2,3-Dichloro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	458





¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.42 (m, 2 H), 1.72 (m, 2 H), 2.78 (q, J=6.44 Hz, 2 H), 2.91 (m, 1 H), 3.09 (m, 3 H), 3.25 (m, 1 H), 3.55 (m, 1 H), 3.70 (s, 3 H), 3.71 (s, 3 H), 3.73 (s, 3 H), 3.83 (s, 3 H), 4.10 (m, 1 H), 4.34 (m, 1 H), 6.75 (s, 1 H), 6.79 (s, 1 H), 7.17 (m, 2 H), 7.22 (m, 1 H), 7.32 (m, 1 H), 10.29 (s, 1 H)





237		2,4,5-Trichloro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	492
238		5-Bromo-2-methoxy-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	498
239		N-[4-(7-Nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-trifluoromethoxybenzenesulfonamide hydrochloride	474
240		2-Nitro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-trifluoromethylbenzenesulfonamide hydrochloride	503






241		3-Fluoro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride		408
242		2,3-Dichloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D ₆) δ ppm 1.45 (m, 2 H), 1.72 (m, 2 H), 2.87 (m, 3 H), 3.09 (m, 3 H), 3.22 (m, 1 H), 3.57 (m, 1 H), 3.70 (s, 3 H), 3.71 (s, 3 H), 4.07 (m, 1 H), 4.33 (m, 1 H), 6.75 (s, 1 H), 6.79 (s, 1 H), 7.56 (t, J=7.98 Hz, 1 H), 7.94 (ddd, J=7.98, 5.42, 1.54 Hz, 2 H), 8.18 (t, J=5.64 Hz, 1 H), 10.29 (s, 1 H)	473
243		2,4,5-Trichloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	¹ H NMR (300 MHz, DMSO-D ₆) δ ppm 1.45 (m, 2 H), 1.69 (m, 2 H), 2.89 (m, 3 H), 3.10 (m, 3 H), 3.24 (m, 1 H), 3.58 (m, 1 H), 3.70 (s, 3 H), 3.71 (s, 3 H), 4.10 (m, 1 H), 4.34 (m, 1 H), 6.75 (s, 1 H), 6.79 (s, 1 H), 8.06 (s, 1 H), 8.13 (s, 1 H), 8.26 (t, J=5.64 Hz, 1 H), 10.18 (s, 1 H)	507
244		4-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride		513






245		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-(trifluoromethoxy)benzenesulfonamide hydrochloride	489
246		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-nitro-4-(trifluoromethyl)benzenesulfonamide	518
247		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-3-fluorobenzenesulfonamide hydrochloride	423
248		2,4-Dichloro-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]benzenesulfonamide hydrochloride	458






249		2,4,6-Trimethyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	432
250		N-[4-(7-Nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-trifluoromethyl-benzenesulfonamide hydrochloride	458
251		2-Bromo-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	468
252		4-Methoxy-2,3,6-trimethyl-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	462
253		2-Cyano-N-[4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	415






254		2,4-Dichloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	473
255		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,4,6-trimethyl-benzenesulfonamide hydrochloride	447
256		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-trifluoromethyl-benzenesulfonamide hydrochloride	473
257		2-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	483

258		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,3,6-trimethylbenzenesulfonamide hydrochloride	477
259		2-Cyano-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	430
260		5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-methoxybenzenesulfonamide oxalate	527
261		5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-methoxybenzenesulfonamide oxalate	513






262		N-[6-(3,4-Dihydro-1H-isoquinolin-2-yl)-hexyl]-3-methylbenzenesulfonamide hydrochloride	387
263		N-[6-(3,4-Dihydro-1H-isoquinolin-2-yl)-hexyl]-3-fluorobenzenesulfonamide hydrochloride	391
264		2,4-Dichloro-N-[6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]benzenesulfonamide hydrochloride	441
265		2,4,5-Trichloro-N-[6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]benzenesulfonamide hydrochloride	475
266		5-Bromo-N-[6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-2-methoxybenzenesulfonamide hydrochloride	481





267		4-Chloro-N-[6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-2,5-dimethylbenzenesulfonamide hydrochloride	435
268		Naphthalene-1-sulfonic acid [6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-amide hydrochloride	423
269		Naphthalene-2-sulfonic acid [6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-amide oxalate	423
270		Benzo[b]thiophene-2-sulfonic acid [6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-amide oxalate	429
271		Thiophene-2-sulfonic acid [6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-amide hydrochloride	379





272		N-[6-(3,4-Dihydro-1H-isoquinolin-2-yl)-hexyl]-2-nitro-benzenesulfonamide hydrochloride	418
273		5-Chloro-3-methyl-benzothienophene-2-sulfonic acid [6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-amide hydrochloride	477
274		4-Methyl-naphthalene-1-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	409
275		4-Methyl-naphthalene-1-sulfonic acid [5-(3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	423
276		4-Methyl-naphthalene-1-sulfonic acid [6-(3,4-dihydro-1H-isoquinolin-2-yl)-hexyl]-amide hydrochloride	437





277		4-Methyl-naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	469
278		4-Methyl-naphthalene-1-sulfonic acid [5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	483
279		4-Methyl-naphthalene-1-sulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	454
280		4-Methyl-naphthalene-1-sulfonic acid [5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	468
281		5-Isoxazol-5-yl-thiophene-2-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	418





¹H NMR (300 MHz, DMSO-D₆) δ ppm 1.50 (m, 2 H), 1.78 (m, 2 H), 2.92 (q, J=6.74 Hz, 2 H), 3.01 (m, 1 H), 3.13 (m, 3 H), 3.22 (m, 1 H), 3.64 (m, 1 H), 4.22 (dd, J=15.45, 8.13 Hz, 1 H), 4.46 (m, 1 H), 7.10 (s, 1 H), 7.22 (m, 4 H), 7.69 (d, J=3.95 Hz, 1 H), 7.76 (d, J=3.95 Hz, 1 H), 8.20 (t, J=5.78 Hz, 1 H), 8.73 (d, J=1.90 Hz, 1 H), 10.54 (s, 1 H)






282		5-Isloxazol-5-yl-thiophene-2-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	478
283		5-Isloxazol-5-yl-thiophene-2-sulfonic acid [5-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	492
284		5-Isloxazol-5-yl-thiophene-2-sulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	463
285		5-Isloxazol-5-yl-thiophene-2-sulfonic acid [5-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-pentyl]-amide hydrochloride	477
286		3,5-Dichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-hydroxybenzenesulfonamide hydrochloride	429






287		3,5-Dichloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-hydroxybenzenesulfonamide hydrochloride	429
288		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2-methoxy-4-methylbenzenesulfonamide hydrochloride	389
289		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-2,4-difluorobenzenesulfonamide hydrochloride	381
290		3,5-Dichloro-4-hydroxybenzenesulfonic acid 2,6-dichloro-4-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butylsulfamoyl]phenyl ester hydrochloride	653






291		3,5-Dichloro-2-hydroxybenzenesulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butylsulfamoyl]-phenyl ester hydrochloride	653
292		4-Chloro-naphthalene-1-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	429
293		4-Fluoro-naphthalene-1-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	413
294		Dibenzofuran-2-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	435






295	 HCl	2,3-Dihydro-benzofuran-5-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	387
296	 HCl	Biphenyl-2-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	421
297	 HCl	1,2-Dimethyl-1H-imidazole-4-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	363
298	 HCl	5-Isoxazol-5-yl-thiophene-2-sulfonic acid [4-(7-pyrrol-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	483






299		4-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,5-difluorobenzenesulfonamide hydrochloride	475
300		4-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]benzenesulfonamide hydrochloride	483
301		5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	509
302		Naphthalene-1-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	455

303		Naphthalene-2-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	455
304		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	405
305		Thiophene-2-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	411
306		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-3-(trifluoromethyl)-benzenesulfonamide hydrochloride	473
307		2,6-Dichloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide	473






308		5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,4-difluorobenzenesulfonamide hydrochloride	519
309		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-ethylbenzenesulfonamide hydrochloride	433
310		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-methoxy-4-methylbenzenesulfonamide hydrochloride	449
311		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-4-methoxybenzenesulfonamide hydrochloride	435
312		1-Methyl-1H-imidazole-4-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	409


313		Benzo[b]thiophene-2-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	461
314		6-Chloro-imidazo[2,1-b]thiazole-5-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	485
315		Benzo[b]thiophene-3-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	461
316		7-Chloro-benzo[1,2,5]oxadiazole-4-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide	481
317		Thiophene-3-sulfonic acid [4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide	411

318		3-{4-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butylsulfamoyl]-phenyl}-propionic acid methyl ester hydrochloride	491
319		3-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	483
320		4-tert-Butyl-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	461
321		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-methanesulfonylbenzenesulfonamide hydrochloride	483
322		3-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2-methylbenzenesulfonamide hydrochloride	453

323		5-Dimethylamino-1-naphthalene-1-sulfonic acid [4-(7-nitro-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	483
324		4-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]sulfamoyl]-2,5-dimethyl-furan-3-carboxylic acid methyl ester hydrochloride	421
325		2-Oxo-2,3-dihydro-benzothiazole-6-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	418
326		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-butyl]-4-fluoro-3-methyl-benzenesulfonamide hydrochloride	377
327		2-Oxo-2,3-dihydro-benzoxazole-6-sulfonic acid [4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-amide hydrochloride	402

328		4-Cyclohexyl-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	427
329		3-Cyano-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride	430
330		2-Chloro-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-5-(trifluoromethyl)benzenesulfonamide hydrochloride	507
331		N-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-3,4-dimethylbenzenesulfonamide hydrochloride	433
332			632

333				638
334		3-Cyano-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzenesulfonamide hydrochloride		370
335		2-Chloro-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-5-trifluoromethylbenzenesulfonamide hydrochloride		447
336		N-[4-(3,4-Dihydro-1H-isoquinolin-2-yl)-3,4-dimethylphenyl]-benzenesulfonamide hydrochloride		373
337		N-{5-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butylsulfamoyl]-naphthalen-1-yl}-succinamic acid		570

338		3-[4-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butylsulfamoyl]-thiophene-2-carboxylic acid methyl ester trifluoroacetate	469
-----	---	--	-----

BIOLOGICAL ASSAYS

Radioligand binding


Radioligand binding assays were performed using the Cloned Human Serotonin Receptor, Subtype 7 (h5HT₇), expressed in CHO cells, coated on Flashplate (Basic FlashPlate Cat.: SMP200) from PerkinElmer (Cat.: 6120512). The protocol assay was essentially the recommended protocol in the Technical Data Sheet by PerkinElmer Life and Analytical Sciences. The Mass membrane protein/well was typically 12 µg and the Receptor/well was about 9–10 fmoles. The Flashplate were let equilibrate at room temperature for one hour before the addition of the components of the assay mixture. The binding buffer was: 50 mM Tris-HCl, pH 7.4, containing 10 mM MgCl₂, 0.5 mM EDTA and 0.5% BSA. The radioligand was [¹²⁵I]LSD at a final concentration of 0.82 nM. Nonspecific binding was determined with 50 µM of Clozapine. The assay volume was 25 µl. TopSeal-A were applied onto Flashplate microplates and they were incubated at room temperature for 240 minutes in darkness. The radioactivity were quantified by liquid scintillation spectrophotometry (Wallac 1450 Microbeta Trilux) with a count delay of 4 minutes prior to counting and a counting time of 30 seconds per well. Competition binding data were analyzed by using the LIGAND program (Munson and Rodbard, LIGAND: A versatile, computerized approach for characterization of ligand-binding systems. *Anal. Biochem.* 107: 220-239, 1980) and assays were performed in triplicate determinations for each point. Results for representative compounds are given in the table 2 below:

Table 2

COMPOUND	5-HT7 IC-50 (nM)
2	59.2
5	33.2
116	31.1
118	39.2
140	60.8
142	80.4
151	39
160	74.4
210	37.3
220	67.4
235	68.4
257	57.2

CLAIMS

1. A compound of the formula I:



(I)

wherein

W is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are each independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, -COR₈, -C(O)OR₈, -C(O)NR₈R₉, -C=NR₈, -CN, -OR₈, -OC(O)R₈, -S(O)_t-R₈, -NR₈R₉, -NR₈C(O)R₉, -NO₂, -N=CR₈R₉ or halogen, wherein

t is 1, 2 or 3;

R₈ and R₉ are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, halogen;

n is 4, 5 or 6;


or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.

2. A compound according to claim 1 characterized in that n is 4 or 5, preferably 4.


3. A compound according to claim 1 or 2 characterized in that W is an aromatic group selected from substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, preferably substituted or unsubstituted phenyl.

4. A compound according to claim 3 characterized in that W is selected from alkyl, alkoxy and/or halo substituted phenyl.
5. A compound according to any of the preceding claims characterized in that R₅, R₆ and R₇ are H.
6. A compound according to any of the preceding claims characterized in that R₁ and R₄ are H.
7. A compound according to claims 5 and 6 wherein R₂ and R₃ are alkoxy, preferably methoxy.

8. A process for the preparation of a compound of formula (I) or a salt, isomer or solvate thereof as claimed in any of claims 1-7, which comprises the coupling of a compound of Formula (II):



in which R₁-R₇ and n are as defined in Formula (I), with a compound of Formula (III):



in which W is as defined in Formula (I) and X is an halogen, preferably Cl.

9. A pharmaceutical composition which comprises a compound as defined in any of claims 1-7 or a pharmaceutically acceptable salt, prodrug, isomer or solvate thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
10. A pharmaceutical composition according to claim 9 for oral administration.
11. Use of a compound as defined in any of claims 1-7 in the manufacture of a medicament.
12. Use according to claim 11 wherein the medicament is for the treatment of a 5-HT₇ mediated disease or condition.
13. Use according to claim 12 wherein the disease is sleep disorder, shift worker syndrome, jet lag, depression, seasonal affective disorder, migraine, anxiety, psychosis, schizophrenia, pain, cognition and memory disorders, neuronal degeneration resulting from ischemic events, cardiovascular diseases such as hypertension, irritable bowel syndrome, inflammatory bowel disease, spastic colon or urinary incontinence.
14. A method for treating or preventing a central nervous disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound as defined in any of claims 1-7, or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/008978

A. CLASSIFICATION OF SUBJECT MATTER

C07D217/04 C07D413/14 C07D409/12 C07D401/12 C07D513/04
C07D413/12 C07D417/12 A61K31/47 A61K31/4725 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/037887 A1 (ASTRAZENECA AB; ANGST, CHRISTOF; HAEBERLEIN, MARKUS; HILL, DANIEL; JAC) 8 May 2003 (2003-05-08) examples	1-14
A	WO 97/29097 A1 (SMITHKLINE BEECHAM PLC; FORBES, IAN, THOMSON) 14 August 1997 (1997-08-14) cited in the application examples	1-14
A	WO 97/49695 A1 (SMITHKLINE BEECHAM P.L.C; FORBES, IAN, THOMSON; RAHMAN, SHIRLEY, KATHE) 31 December 1997 (1997-12-31) cited in the application examples	1-14
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

25 January 2006

Date of mailing of the international search report

02/02/2006

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Menegaki, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/008978

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BON, ERIC; BIGG, DENNIS ET AL: "Aluminium chloride promoted aminolysis of N-Tosyl lactams" JOURNAL OF ORGANIC CHEMISTRY, vol. 59, no. 7, 1994, pages 1904-1906, XP002314959 examples 3a-d -----	1-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2005/008978

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 14 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/008978

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03037887	A1	08-05-2003	BR 0213778 A	09-11-2004
			CA 2464342 A1	08-05-2003
			CN 1608061 A	20-04-2005
			EP 1451172 A1	01-09-2004
			JP 2005516896 T	09-06-2005
			MX PA04004076 A	23-07-2004
			ZA 200403240 A	07-04-2005

WO 9729097	A1	14-08-1997	EP 0883613 A1	16-12-1998
			JP 2000504677 T	18-04-2000

WO 9749695	A1	31-12-1997	EP 0912550 A1	06-05-1999
			JP 2000512646 T	26-09-2000
			US 6025367 A	15-02-2000
